Fibroma
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Maneesha Nandimandalam, M.B.B.S.[2],Simrat Sarai, M.D. [3]
Synonyms and keywords: Oral Fibroma; Focal fibrous hyperplasia; Peripheral fibroma; Fibroid epulis; Fibroepithelial polyp; Irritation fibroma; Traumatic fibroma; Osteofibrous dysplasia; Congenital osteitis fibrosa; Fibrous metaphyseal defect; Fibroxanthoma of bone; Histiocytic fibrous defect; Histiocytic xanthogranuloma; Fibrous tumor of the pleura; Cemento-ossifying Fibroma; Calcifying fibrous epulis; Peripheral fibroma with calcification; Renal Medullary Fibroma; Sclerotic Fibroma; Desmoplastic Fibroblastoma; Collagenous Fibroma; Uterine Fibroma; Fibromyoma; Fibroleiomyoma
Overview
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Maneesha Nandimandalam, M.B.B.S.[2],Simrat Sarai, M.D. [3]
Overview
Fibromas are benign tumors that are composed of fibrous or connective tissue. They can grow in all organs, arising from mesenchymal tissue. The term “fibroblastic” or “fibromatous” is used to describe tumors of the fibrous connective tissue. There is no classification system established for fibroma. Based on the pathophysiology and location of the tumor, fibroma may be classified into hard fibroma, soft fibroma, angiofibroma, cystic fibroma, chondromyxoid fibroma, desmoplastic fibroma, nonossifying fibroma, ossifying fibroma, nuchal fibroma, collagenous fibroma, fibroma of tendon sheath, perifollicular fibroma, pleomorphic fibroma, uterine fibroma, neurofibroma, and ovarian fibroma. On gross pathology, polypoid lesion which is usually small, is characteristic findings of oral fibroma. On microscopic histopathological analysis, fibrous stroma, collagen bundles, prominent vessels, and overlying squamous mucosa with hyperkeratosis and focal ulceration are characteristic findings of oral fibroma. On gross pathology, well circumscribed, metaphyseal lesion, and fragments of white-grey rubbery tissue are characteristic findings of chondromyxoid fibroma. On microscopic histopathological analysis, spindle cells or stellate cells in a myxoid or chondroid stroma, lobules with hypocellular centers and hypercellular peripheries, giant cells in a hypercellular periphery, and scattered calcifications are characteristic findings of chondromyxoid fibroma. On gross pathology, fleshy, fibrous, yellow or tan-brown lesion with variable areas of haemorrhage are characteristic findings of non-ossifying fibroma. On microscopic histopathological analysis, spindle cells without cytologic atypia are arranged in a storiform pattern, scattered chronic inflammatory cells and benign giant cells, foam cells and hemosiderin deposition, and mitoses are characteristic findings of non-ossifying fibroma. On gross pathology, discrete mass that is well delineated from surrounding bone, tan-white, rubbery cut surface, firm to gritty and no encapsulation are characteristic findings of ossifying fibroma. On microscopic histopathological analysis, haphazardly distributed lamellated bony spicules on a background of fibrous stroma, a zonal architecture with a center of immature bone surrounded by more mature lamellar bone, and central spicules of woven bony trabeculae are lined by a layer of osteoblasts are characteristic findings of ossifying fibroma. Common causes of oral fibroma include trauma or chronic irritation. There are no established causes for chondromyxoid fibroma, non-ossifying fibroma, cemento-ossifying fibroma, and ossifying fibroma. Patients of all age groups may develop fibromas. However, the majority of fibromas are observed in adults. Fibromas usually affects men and women equally, however certain fibromas may show gender predilection. Fibromas are most often observed in adults, but they may occur in individuals of any age and either sex. The majority of patients with fibroma are asymptomatic. The most common symptoms of fibroma include pain and swelling of the affected area. Biopsy is the diagnostic study of choice for fibroma.
Historical Perspective
Ossifying fibroma was first described in 1872 by Menzel. In the year 1927 Montgomery coined the term “ossifying fibroma”. Chondromyxoid fibroma was first described in year 1948 by H L Jaffe and L Lichtenstein. The non-ossifying fibroma (NOF) was first recognized in 1941 by Sontag and Pyle. Desmoplastic fibroma was first described in year 1958 by H L Jaffe.
Classification
There is no classification system established for fibroma. Based on the pathophysiology and location of the tumor, fibroma may be classified into hard fibroma, soft fibroma, angiofibroma, cystic fibroma, chondromyxoid fibroma, desmoplastic fibroma, nonossifying fibroma, ossifying fibroma, nuchal fibroma, collagenous fibroma, fibroma of tendon sheath, perifollicular fibroma, pleomorphic fibroma, uterine fibroma, neurofibroma, and ovarian fibroma.
Pathophysiology
On gross pathology, polypoid lesion which is usually small, is characteristic findings of oral fibroma. On microscopic histopathological analysis, fibrous stroma, collagen bundles, prominent vessels, and overlying squamous mucosa with hyperkeratosis and focal ulceration are characteristic findings of oral fibroma. On gross pathology, well circumscribed, metaphyseal lesion, and fragments of white-grey rubbery tissue are characteristic findings of chondromyxoid fibroma. On microscopic histopathological analysis, spindle cells or stellate cells in a myxoid or chondroid stroma, lobules with hypocellular centers and hypercellular peripheries, giant cells in a hypercellular periphery, and scattered calcifications are characteristic findings of chondromyxoid fibroma. On gross pathology, fleshy, fibrous, yellow or tan-brown lesion with variable areas of haemorrhage are characteristic findings of non-ossifying fibroma. On microscopic histopathological analysis, spindle cells without cytologic atypia are arranged in a storiform pattern, scattered chronic inflammatory cells and benign giant cells, foam cells and hemosiderin deposition, and mitoses are characteristic findings of non-ossifying fibroma. On gross pathology, discrete mass that is well delineated from surrounding bone, tan-white, rubbery cut surface, firm to gritty and no encapsulation are characteristic findings of ossifying fibroma. On microscopic histopathological analysis, haphazardly distributed lamellated bony spicules on a background of fibrous stroma, a zonal architecture with a center of immature bone surrounded by more mature lamellar bone, and central spicules of woven bony trabeculae are lined by a layer of osteoblasts are characteristic findings of ossifying fibroma.
Causes
Common causes of oral fibroma include trauma or chronic irritation. There are no established causes for chondromyxoid fibroma, non-ossifying fibroma, cemento-ossifying fibroma, and ossifying fibroma.
Epidemiology and Demographics
Patients of all age groups may develop fibromas. However, the majority of fibromas are observed in adults. Fibromas usually affects men and women equally, however certain fibromas may show gender predilection. Fibromas are most often observed in adults, but they may occur in individuals of any age and either sex.
Risk Factors
There are no established risk factors for fibroma.
Screening
According to the United States Preventive Services Task Force, screening for fibroma is not recommended among the general population.
Differentiating Fibroma from other Diseases
Oral fibroma must be differentiated from squamous papilloma, giant cell fibroma, neurofibroma, peripheral giant cell granuloma, mucocele, and benign and malignant salivary gland tumors. Non-ossifying fibroma must be differentiated from fibrous cortical defect, aneurysmal bone cyst, chondromyxoid fibroma, fibrous dysplasia, desmoplastic fibroma, giant cell tumor of bone, and spindle cell lesions of bone. Ossifying fibroma must be differentiated from ossifying fibroma, fibrous dysplasia, adamantinoma, and osteoid osteoma. Chondromyxoid fibroma must be differentiated from aneurysmal bone cyst (ABC), giant cell tumor of bone (GCT), non ossifying fibroma, chondroblastoma, chondrosarcoma, and phosphaturic mesenchymal tumor. Desmoplastic fibroma must be differentiated from giant cell tumour of bone (GCT), non ossifying fibroma (NOF), fibrous dysplasia, low grade fibrosarcoma, unicameral bone cyst, chondromyxoid fibroma, periosteal desmoids, eosinophilic granuloma, low-grade intraosseous osteosarcoma, adamantinoma, and distant metastasis.
Natural History, Complications and Prognosis
Common complications of ossifying and non-ossifying fibroma include pathological fractures. Depending on the type of the fibroma, the prognosis may vary. However, the prognosis is generally regarded as excellent for nonossifying fibroma. Ossifying fibromas tend to regress over time. Ossifying fibroma is noninvasive tumor. It will recur if it is excised before skeletal maturity. Excision after skeletal maturity is usually successful. Oral fibromas are benign tumors. Recurrence of oral fibromas is possible, however, if the offending irritant persists. Desmoplastic fibromas are benign and locally aggressive tumors. Desmoplastic fibroma is a rare benign intraosseous tumor neoplasm. Desmoplastic fibroma has a recurrence rate of approximately 37% to 72%. The average rate of recurrence after curettage has been reported to be approximately 55%.
Diagnosis
History and Symptoms
The majority of patients with fibroma are asymptomatic. The most common symptoms of fibroma include pain and swelling of the affected area.
Physical Examination
Common physical examination findings of oral fibroma include sessile, dome-shaped mass, 1-2 cm in diameter, pale pink in color, and firm, non-tender on palpation. Common physical examination findings of non-ossifying fibromas include localized tenderness or swelling over a lesion. Common physical examination findings of cemento-ossifying fibromas include a sessile or pedunculated mass, mass may be ulcerated and generally has a diameter of less than 2 cm, and diffuse expansion of jaw on right maxillary posterior area, extending anteroposteriorly from distal of upper right second premolar to tuberosity region. Common physical examination findings of desmoplastic fibroma include tenderness over the affected area and palpable mass may be present.
X-Ray
X-ray may be helpful in the diagnosis of fibroma. Findings on x-ray suggestive of a particular fibroma depends on the type of the fibroma. Findings on x-ray suggestive of non-ossifying fibromas include sharply demarcated, asymmetrical, and cortically based lucencies with a thin sclerotic rim. Findings on x-ray suggestive of ossifying fibromas include well-circumscribed lesion, intracortical osteolysis with a characteristic sclerotic band, cortical expansion, and a lytic thinning of the diaphyseal cortical bone with interspersed sclerosis. Findings on x-ray suggestive of chondromyxoid fibroma include a lobulated, eccentric radiolucent lesion. Findings on x-ray suggestive of desmoplastic fibroma include a lytic bone lesions with a geographic pattern of bone destruction and a narrow zone of transition and non-sclerotic margins.
CT
CT scan may be helpful in the diagnosis of fibroma. Findings on x-ray suggestive of a particular fibroma depends on the type of the fibroma. Findings on CT scan of ossifying fibroma include a well-circumscribed lesion, intracortical osteolysis with a characteristic sclerotic band, and moderate cortical expansion. Findings on CT scan of non- ossifying fibroma include sharply demarcated, asymmetrical, cortically based lucencies with a thin sclerotic rim. Findings on CT scan of chondromyxoid fibroma include a mild cortical expansion and characteristic lack of mineralization within chondromyxoid fibromas. Findings on CT scan of cemento-ossifying fibroma include a well circumscribed masses which expand the underlying bone.
MRI
MRI may be helpful in the diagnosis of fibroma. On MRI, fibromas appear isointense or hypointense on T1 sequences and hyperintense on T2 sequences.
Ultrasound
Ultrasound may be helpful in the diagnosis of fibroma. Findings on ultrasound suggestive of fibroma include solid, hypoechoic masses with ultrasound beam attenuation.
Other Imaging Findings
Other imaging studies for ossifying fibroma include bone scan, which demonstrates mild hyperemia and moderate bone uptake during healing. However, in general they are negative.
Other Diagnostic Studies
Biopsy is the diagnostic study of choice for fibroma.
Treatment
Medical Therapy
There are no much options available in medical therapy for most of the fibromas, but for some one’s like uterine fibroma does have medical therapy. Gonadotropin-releasing hormone analogues like Leuprolide, Buserelin, Nafarelin, Deslorelin, Histrelin, Goserelin are commonly used. GnRH analogues with add-back therapy like progestins alone, estrogen alone, combined estrogen and progesterone, tibolone, and raloxifene.
Surgery
Benign fibromas can be removed or left alone. A physician should examine the fibroma and determine whether it may be malignant. For most fibromas the definitive treatment is complete excision. The standard treatment for uterine fibroids include uterus resection (hysterectomy. Segmentary myomectomy is a conservative surgical procedure that consists of resecting the tumor, with the preservation of uterus and, therefore the reproductive function. Bilateral uterine artery embolisation is used as an alternative approach to surgery.
Primary Prevention
There are no primary preventive measures for fibroma.
Secondary Prevention
There is no secondary prevention for fibromas.
References
Historical Perspective
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Maneesha Nandimandalam, M.B.B.S.[2],Simrat Sarai, M.D. [3]
Overview
Ossifying fibroma was first described in 1872 by Menzel. In the year 1927 Montgomery coined the term “ossifying fibroma”. Chondromyxoid fibroma was first described in the year 1948 by H L Jaffe and L Lichtenstein. The non-ossifying fibroma (NOF) was first recognized in 1941 by Sontag and Pyle. Desmoplastic fibroma was first described in the year 1958 by H L Jaffe.
Historical Perspective
- Chondromyxoid fibroma was first described in the year 1948 by H L Jaffe and L Lichtenstein.[1]
- Desmoplastic fibroma was first described in the year 1958 by H L Jaffe.[2]
- Giant cell fibroma was first described in the year 1974 by Weathers and Callihan.[3]
- Solitary fibrous tumor (SFT) was first described in the pleura in 1931. The first discussion of its clinical and pathological properties was by Klemperer and Rabin.
- Pleural fibroma was first mentioned in the scientific literature by Wagner. The first discussion of its clinical and pathological properties was by Klemperer and Rabin.
- Elastofibroma was first described in the year 1959 by O H Jarvi and A E Saxon.
- Ossifying fibroma was first described in 1872 by Menzel. In the year 1927 Montgomery coined the term “ossifying fibroma”.
- The non-ossifying fibroma (NOF) was first recognized in 1941 by Sontag and Pyle.[4]
Landmark Events in the Development of Treatment Strategies
References
- ↑ Shen, Shuai; Chen, Miao; Jug, Rachel; Yu, Cheng-Qian; Zhang, Wan-Lin; Yang, Lian-He; Wang, Liang; Yu, Juan-Han; Lin, Xu-Yong; Xu, Hong-Tao; Ma, Shuang (2017). “Radiological presentation of chondromyxoid fibroma in the sellar region”. Medicine. 96 (49): e9049. doi:10.1097/MD.0000000000009049. ISSN 0025-7974.
- ↑ Nedopil A, Raab P, Rudert M (2013). “Desmoplastic fibroma: a case report with three years of clinical and radiographic observation and review of the literature”. Open Orthop J. 8: 40–6. doi:10.2174/1874325001307010040. PMC 3583030. PMID 23459513.
- ↑ Seitz SD, Dinh TN, Yoon TY (October 2017). “Melanotic Macule in Conjunction with a Giant Cell Fibroma”. J Contemp Dent Pract. 18 (10): 981–985. PMID 28989141.
- ↑ Bowers LM, Cohen DM, Bhattacharyya I, Pettigrew JC, Stavropoulos MF (2013). “The non-ossifying fibroma: a case report and review of the literature”. Head Neck Pathol. 7 (2): 203–10. doi:10.1007/s12105-012-0399-7. PMC 3642261. PMID 23008139.
Classification
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Maneesha Nandimandalam, M.B.B.S.[2],Simrat Sarai, M.D. [3]
Overview
There is no classification system established for fibroma. Based on the pathophysiology and location of the tumor, fibroma may be classified into hard fibroma, soft fibroma, angiofibroma, cystic fibroma, chondromyxoid fibroma, desmoplastic fibroma, nonossifying fibroma, ossifying fibroma, nuchal fibroma, collagenous fibroma, fibroma of tendon sheath, perifollicular fibroma, pleomorphic fibroma, uterine fibroma, neurofibroma, and ovarian fibroma.[1]
Classification
Based on the pathophysiology and location of the tumor fibroma may be classified into the following types, which is shown below in a tabular form:[2][3][4] [5][6][7][8] [9][10][11] [12][13] [14]
| Type of Fibroma | Features |
|---|---|
|
|
|
|
|
|
|
References
- ↑ fibroma. Wikipedia(2015) https://en.wikipedia.org/wiki/Fibroma Accessed on February 25, 2016
- ↑ Boujoual M, Hakimi I, Kouach J, Oukabli M, Moussaoui DR, Dehayni M (2015). “Large twisted ovarian fibroma in menopausal women: a case report”. Pan Afr Med J. 20: 322. doi:10.11604/pamj.2015.20.322.5998. PMC 4491469. PMID 26175813.
- ↑ Chen H, Liu Y, Shen LF, Jiang MJ, Yang ZF, Fang GP (November 2016). “Ovarian thecoma-fibroma groups: clinical and sonographic features with pathological comparison”. J Ovarian Res. 9 (1): 81. doi:10.1186/s13048-016-0291-2. PMC 5120502. PMID 27876070.
- ↑ Matsuda K, Tateishi S, Akazawa Y, Kinoshita A, Yoshida S, Morisaki S, Fukushima A, Matsuwaki T, Yoshiura KI, Nakashima M (October 2016). “Rapid growth of mitotically active cellular fibroma of the ovary: a case report and review of the literature”. Diagn Pathol. 11 (1): 101. doi:10.1186/s13000-016-0554-7. PMID 27770806.
- ↑ Takenaga RK, Frassica FJ, McCarthy EF (2007). “Subperiosteal chondromyxoid fibroma: a report of two cases”. Iowa Orthop J. 27: 104–7. PMC 2150655. PMID 17907440.
- ↑ Sharma H, Jane MJ, Reid R (June 2006). “Chondromyxoid fibroma of the foot and ankle: 40 years’ Scottish bone tumour registry experience”. Int Orthop. 30 (3): 205–9. doi:10.1007/s00264-005-0046-y. PMC 2532097. PMID 16547720.
- ↑ Manta L, Suciu N, Toader O, Purcărea RM, Constantin A, Popa F (2016). “The etiopathogenesis of uterine fibromatosis”. J Med Life. 9 (1): 39–45. PMC 5152611. PMID 27974911.
- ↑ Borahay MA, Al-Hendy A, Kilic GS, Boehning D (April 2015). “Signaling Pathways in Leiomyoma: Understanding Pathobiology and Implications for Therapy”. Mol. Med. 21: 242–56. doi:10.2119/molmed.2014.00053. PMC 4503645. PMID 25879625.
- ↑ Wang TT, Zhang R, Wang L, Chen Y, Dong Q, Li TJ (March 2014). “Two cases of multiple ossifying fibromas in the jaws”. Diagn Pathol. 9: 75. doi:10.1186/1746-1596-9-75. PMC 3974450. PMID 24678936.
- ↑ Chen Y, Hu DY, Wang TT, Zhang R, Dong Q, Xu ZX, Wang L, Li TJ (September 2016). “CDC73 gene mutations in sporadic ossifying fibroma of the jaws”. Diagn Pathol. 11 (1): 91. doi:10.1186/s13000-016-0532-0. PMC 5034632. PMID 27658992.
- ↑ Bowers LM, Cohen DM, Bhattacharyya I, Pettigrew JC, Stavropoulos MF (June 2013). “The non-ossifying fibroma: a case report and review of the literature”. Head Neck Pathol. 7 (2): 203–10. doi:10.1007/s12105-012-0399-7. PMID 23008139.
- ↑ Schneider M, Zimmermann AC, Depprich RA, Kübler NR, Engers R, Naujoks CD, Handschel J (November 2009). “Desmoplastic fibroma of the mandible–review of the literature and presentation of a rare case”. Head Face Med. 5: 25. doi:10.1186/1746-160X-5-25. PMID 19930688.
- ↑ Aremu AA, Oyedeji OA, Asaleye CM, Adetiloye VA (2013). “An elusive chest coin in an African child: a pleural fibroma’s long, tortuous path to freedom”. Pan Afr Med J. 14: 16. doi:10.11604/pamj.2013.14.16.1874. PMC 3597858. PMID 23503999.
- ↑ Torimitsu S, Nemoto T, Wakayama M, Okubo Y, Yokose T, Kitahara K, Ozawa T, Nakayama H, Shinozaki M, Sasai D, Ishiwatari T, Takuma K, Shibuya K (March 2012). “Literature survey on epidemiology and pathology of cardiac fibroma”. Eur. J. Med. Res. 17: 5. doi:10.1186/2047-783X-17-5. PMC 3351722. PMID 22472419.
Pathophysiology
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Maneesha Nandimandalam, M.B.B.S.[2], Simrat Sarai, M.D. [3]
Overview
On gross pathology, polypoid lesion which is usually small, are characteristic findings of oral fibroma. On microscopic histopathological analysis, fibrous stroma, collagen bundles, prominent vessels, and overlying squamous mucosa with hyperkeratosis and focal ulceration are characteristic findings of oral fibroma. On gross pathology, well circumscribed, metaphyseal lesion, and fragments of white-grey rubbery tissue are characteristic findings of chondromyxoid fibroma. On microscopic histopathological analysis, spindle cells or stellate cells in a myxoid or chondroid stroma, lobules with hypocellular centers and hypercellular peripheries, giant cells in a hypercellular periphery, and scattered calcifications are characteristic findings of chondromyxoid fibroma. On gross pathology, fleshy, fibrous, yellow or tan-brown lesion with variable areas of haemorrhage are characteristic findings of non-ossifying fibroma. On microscopic histopathological analysis, spindle cells without cytologic atypia are arranged in a storiform pattern, scattered chronic inflammatory cells and benign giant cells, foam cells and hemosiderin deposition, and mitoses are characteristic findings of non-ossifying fibroma. On gross pathology, discrete mass that is well delineated from surrounding bone, tan-white, rubbery cut surface, firm to gritty and no encapsulation are characteristic findings of ossifying fibroma. On microscopic histopathological analysis, haphazardly distributed lamellated bony spicules on a background of fibrous stroma, a zonal architecture with a center of immature bone surrounded by more mature lamellar bone, and central spicules of woven bony trabeculae are lined by a layer of osteoblasts are characteristic findings of ossifying fibroma.[1][2]
Pathophysiology
| Type of fibroma | Location | Gross pathology | Microscpoic pathology | Genetics and Immunohistochemistry | Associated conditions |
|---|---|---|---|---|---|
| Ovarian Fibroma [3][4][5][6][7][8][9][10] |
|
|
|
| |
| Oral Fibroma [11][12][13] |
|
|
| ||
| Chondromyxoid fibroma [14][15][16][17][18][19][20][21][22] |
|
|
|
|
|
| Uterine fibroma [23][24][25][26][27][28][29][30][31][32][33] |
|
|
|
| |
| Ossifying Fibroma [34][35][36][37][38][39][40] |
|
|
|
| |
| Non-ossifying Fibroma [41][42][43] |
|
|
|
|
|
| Desmoplastic Fibroma [44][45][46][47][48][49][50] |
|
|
| ||
| Pleural Fibroma [51][52][53][54][55][56][57][58][59][60][61][62] |
|
|
| ||
| Cardiac Fibroma [63][64][65][66][67][68][69][70][71][72] |
|
|
|
|
|
| Renal Medullary Fibroma [73][74][75] |
|
|
|
| |
| Cemento-ossifying Fibroma [76][77][78][79][80][81][82][83][84][85] |
|
|
|
|
|
| Desmoplastic Fibroblastoma [86][87][88][89][90][91] |
|
|
|
| |
| Elastofibroma [92][93][94][95][96][97][98] |
|
|
|
|
|
| Sclerotic Fibroma [99][100][101][102][103][104][105][106][107] |
|
|
|||
| Giant cell fibroma [108][109][110][111][112][113][114][115] |
|
|
|
| |
| Peripheral Odontogenic Fibroma [116][117][118][119][120] | Firm, slowly growing, sessile, and nodular growth of the gingiva are characteristic findings of peripheral odontogenic fibroma. |
|
|
|
Gross Pathology and Microscopic Pathology
| Type of fibroma | Gross image | Microscopic image |
|---|---|---|
| Ovarian fibroma | ![]() |
![]() |
| Oral fibroma | ![]() |
![]() |
| Chondromyxoid fibroma | ||
| Uterine fibroma | ![]() |
![]() |
| Ossifying Fibroma | ![]() | |
| Cardiac fibroma | ![]() |
![]() |
| Giant cell fibroma | ![]() |
![]() |
| Peripheral odontogenic fibroma | ![]() |
![]() |
| Elastofibroma | ![]() |
![]() |
| Desmoplastic fibroblastoma | ![]() | |
| Renal medullary fibroma | ![]() |
![]() |
| Pleural fibroma | ![]() |
|
Pathophysiology
Physiology
The normal physiology of [name of process] can be understood as follows:
Pathogenesis
- The exact pathogenesis of [disease name] is not completely understood.
OR
- It is understood that [disease name] is the result of / is mediated by / is produced by / is caused by either [hypothesis 1], [hypothesis 2], or [hypothesis 3].
- [Pathogen name] is usually transmitted via the [transmission route] route to the human host.
- Following transmission/ingestion, the [pathogen] uses the [entry site] to invade the [cell name] cell.
- [Disease or malignancy name] arises from [cell name]s, which are [cell type] cells that are normally involved in [function of cells].
- The progression to [disease name] usually involves the [molecular pathway].
- The pathophysiology of [disease/malignancy] depends on the histological subtype.
Genetics
[Disease name] is transmitted in [mode of genetic transmission] pattern.
OR
Genes involved in the pathogenesis of [disease name] include:
- [Gene1]
- [Gene2]
- [Gene3]
OR
The development of [disease name] is the result of multiple genetic mutations such as:
- [Mutation 1]
- [Mutation 2]
- [Mutation 3]
Associated Conditions
Conditions associated with [disease name] include:
- [Condition 1]
- [Condition 2]
- [Condition 3]
| Type of fibroma | Location | Gross pathology | Microscpoic pathology | Genetics and Immunohistochemistry | Associated conditions |
|---|---|---|---|---|---|
| Ovarian Fibroma [3][4][5][6][7][8][9][10] |
|
|
|
| |
| Oral Fibroma [11][12][13] |
|
|
| ||
| Chondromyxoid fibroma [14][15][16][17][18][19][20][21][22] |
|
|
|
|
|
| Uterine fibroma [23][24][25][26][27][28][29][30][31][32][33] |
|
|
|
| |
| Ossifying Fibroma [34][35][36][37][38][39][40] |
|
|
|
| |
| Non-ossifying Fibroma [41][42][43] |
|
|
|
|
|
| Desmoplastic Fibroma [44][45][46][47][48][49][50] |
|
|
| ||
| Pleural Fibroma [51][52][53][54][55][56][57][58][59][60][61][62] |
|
|
| ||
| Cardiac Fibroma [63][64][65][66][67][68][69][70][71][72] |
|
|
|
|
|
| Renal Medullary Fibroma [73][74][75] |
|
|
|
| |
| Cemento-ossifying Fibroma [76][77][78][79][80][81][82][83][84][85] |
|
|
|
|
|
| Desmoplastic Fibroblastoma [86][87][88][89][90][91] |
|
|
|
| |
| Elastofibroma [92][93][94][95][96][97][98] |
|
|
|
|
|
| Sclerotic Fibroma [99][100][101][102][103][104][105][106][107] |
|
|
|||
| Giant cell fibroma [108][109][110][111][112][113][114][115] |
|
|
|
| |
| Peripheral Odontogenic Fibroma [116][117][118][119][120] | Firm, slowly growing, sessile, and nodular growth of the gingiva are characteristic findings of peripheral odontogenic fibroma. |
|
|
|
| Type of fibroma | Gross image | Microscopic image |
|---|---|---|
| Ovarian fibroma | ![]() |
![]() |
| Oral fibroma | ![]() |
![]() |
| Chondromyxoid fibroma | ||
| Uterine fibroma | ![]() |
![]() |
| Ossifying Fibroma | ![]() | |
| Cardiac fibroma | ![]() |
![]() |
| Giant cell fibroma | ![]() |
![]() |
| Peripheral odontogenic fibroma | ![]() |
![]() |
| Elastofibroma | ![]() |
![]() |
| Desmoplastic fibroblastoma | ![]() | |
| Renal medullary fibroma | ![]() |
![]() |
| Pleural fibroma | ![]() |
|
References
- ↑ Fibroma. Libre pathology(2015) http://librepathology.org/wiki/Fibroma Accessed on March 12, 2016
- ↑ Fibroma. Radiopedia(2015) http://radiopaedia.org/search?utf8=%E2%9C%93&q=fibroma&scope=all Accessed on March 12, 2016
- ↑ 3.0 3.1 Boujoual M, Hakimi I, Kouach J, Oukabli M, Moussaoui DR, Dehayni M (2015). “Large twisted ovarian fibroma in menopausal women: a case report”. Pan Afr Med J. 20: 322. doi:10.11604/pamj.2015.20.322.5998. PMC 4491469. PMID 26175813.
- ↑ 4.0 4.1 Chen H, Liu Y, Shen LF, Jiang MJ, Yang ZF, Fang GP (November 2016). “Ovarian thecoma-fibroma groups: clinical and sonographic features with pathological comparison”. J Ovarian Res. 9 (1): 81. doi:10.1186/s13048-016-0291-2. PMC 5120502. PMID 27876070.
- ↑ 5.0 5.1 Matsuda K, Tateishi S, Akazawa Y, Kinoshita A, Yoshida S, Morisaki S, Fukushima A, Matsuwaki T, Yoshiura KI, Nakashima M (October 2016). “Rapid growth of mitotically active cellular fibroma of the ovary: a case report and review of the literature”. Diagn Pathol. 11 (1): 101. doi:10.1186/s13000-016-0554-7. PMID 27770806.
- ↑ 6.0 6.1 Yamada T, Hattori K, Satomi H, Hirose Y, Nakai G, Daimon A, Hayashi A, Terai Y, Ohmichi M, Fukunaga M (October 2015). “Mitotically active cellular fibroma of the ovary: a case report and literature review”. J Ovarian Res. 8: 65. doi:10.1186/s13048-015-0191-x. PMC 4595272. PMID 26437718.
- ↑ 7.0 7.1 Zong L, Lin M, Fan X (2014). “Mitotically active cellular fibroma of ovary should be differentiated from fibrosarcoma: a case report and review of literature”. Int J Clin Exp Pathol. 7 (11): 7578–82. PMC 4270577. PMID 25550794.
- ↑ 8.0 8.1 Parwate NS, Patel SM, Arora R, Gupta M (December 2016). “Ovarian Fibroma: A Clinico-pathological Study of 23 Cases with Review of Literature”. J Obstet Gynaecol India. 66 (6): 460–465. doi:10.1007/s13224-015-0717-6. PMC 5080219. PMID 27821988.
- ↑ 9.0 9.1 Finch T, Pushpanathan C, Brown K, El-Gohary Y (June 2012). “Gorlin syndrome presenting with a unilateral ovarian fibroma in a 22-year-old woman: a case report”. J Med Case Rep. 6: 148. doi:10.1186/1752-1947-6-148. PMID 22691621.
- ↑ 10.0 10.1 Yazdani S, Alijanpoor A, Sharbatdaran M, Bouzari Z, Abedisamakoosh M, Lakaieandi F, Mohammadpour M (2014). “Meigs’ syndrome with elevated serum CA125 in a case of ovarian fibroma /thecoma”. Caspian J Intern Med. 5 (1): 43–5. PMC 3894471. PMID 24490014.
- ↑ 11.0 11.1 Panta P (2015). “Traumatic fibroma”. Pan Afr Med J. 21: 220. doi:10.11604/pamj.2015.21.220.7498. PMC 4587079. PMID 26448815.
- ↑ 12.0 12.1 Christopoulos P, Sklavounou A, Patrikiou A (April 1994). “True fibroma of the oral mucosa: a case report”. Int J Oral Maxillofac Surg. 23 (2): 98–9. PMID 8035060.
- ↑ 13.0 13.1 Krishnan V, Shunmugavelu K (2015). “A clinical challenging situation of intra oral fibroma mimicking pyogenic granuloma”. Pan Afr Med J. 22: 263. doi:10.11604/pamj.2015.22.263.8080. PMC 4765330. PMID 26958126.
- ↑ 14.0 14.1 Takenaga RK, Frassica FJ, McCarthy EF (2007). “Subperiosteal chondromyxoid fibroma: a report of two cases”. Iowa Orthop J. 27: 104–7. PMC 2150655. PMID 17907440.
- ↑ 15.0 15.1 Sharma H, Jane MJ, Reid R (June 2006). “Chondromyxoid fibroma of the foot and ankle: 40 years’ Scottish bone tumour registry experience”. Int Orthop. 30 (3): 205–9. doi:10.1007/s00264-005-0046-y. PMC 2532097. PMID 16547720.
- ↑ 16.0 16.1 Yasuda T, Nishio J, Sumegi J, Kapels KM, Althof PA, Sawyer JR, Reith JD, Bridge JA (November 2009). “Aberrations of 6q13 mapped to the COL12A1 locus in chondromyxoid fibroma”. Mod. Pathol. 22 (11): 1499–506. doi:10.1038/modpathol.2009.101. PMID 19648885.
- ↑ 17.0 17.1 Choi YS, Kim BS, Joo JE, Park YK, Lee SH, Song BY (2011). “A rare case of epiphyseal chondromyxoid fibroma of the proximal tibia”. Korean J Radiol. 12 (6): 761–4. doi:10.3348/kjr.2011.12.6.761. PMC 3194784. PMID 22043162.
- ↑ 18.0 18.1 Gutiérrez-González R, De Reina L, Saab A, Jiménez-Heffernan J, García-Uría J (June 2012). “Chondromyxoid fibroma of the lumbar spine: case report and literature review”. Eur Spine J. 21 Suppl 4: S458–62. doi:10.1007/s00586-011-2078-x. PMID 22094389.
- ↑ 19.0 19.1 Morris LG, Rihani J, Lebowitz RA, Wang BY (June 2009). “Chondromyxoid fibroma of sphenoid sinus with unusual calcifications: case report with literature review”. Head Neck Pathol. 3 (2): 169–73. doi:10.1007/s12105-009-0121-6. PMID 19644549.
- ↑ 20.0 20.1 Minasian T, Claus C, Hariri OR, Piao Z, Quadri SA, Yuhan R, Leong D, Tashjian V (2016). “Chondromyxoid fibroma of the sacrum: A case report and literature review”. Surg Neurol Int. 7 (Suppl 13): S370–4. doi:10.4103/2152-7806.182547. PMC 4879845. PMID 27274412.
- ↑ 21.0 21.1 Kilic D, Findikcioglu A, Tepeoglu M, Vural C (August 2015). “Chondromyxoid Fibroma of the Sternum in a 63-Year-Old Woman”. Tex Heart Inst J. 42 (4): 400–2. doi:10.14503/THIJ-14-4381. PMC 4567104. PMID 26413029.
- ↑ 22.0 22.1 Fomete B, Adeosun OO, Awelimobor DI, Olayemi L (January 2014). “Chondromyxoid fibroma of the mandible: Case report and review of the literature”. Ann Maxillofac Surg. 4 (1): 78–80. doi:10.4103/2231-0746.133072. PMC 4073468. PMID 24987604.
- ↑ 23.0 23.1 Manta L, Suciu N, Toader O, Purcărea RM, Constantin A, Popa F (2016). “The etiopathogenesis of uterine fibromatosis”. J Med Life. 9 (1): 39–45. PMC 5152611. PMID 27974911.
- ↑ 24.0 24.1 Borahay MA, Al-Hendy A, Kilic GS, Boehning D (April 2015). “Signaling Pathways in Leiomyoma: Understanding Pathobiology and Implications for Therapy”. Mol. Med. 21: 242–56. doi:10.2119/molmed.2014.00053. PMC 4503645. PMID 25879625.
- ↑ 25.0 25.1 Miettinen M, Felisiak-Golabek A, Wasag B, Chmara M, Wang Z, Butzow R, Lasota J (December 2016). “Fumarase-deficient Uterine Leiomyomas: An Immunohistochemical, Molecular Genetic, and Clinicopathologic Study of 86 Cases”. Am. J. Surg. Pathol. 40 (12): 1661–1669. doi:10.1097/PAS.0000000000000703. PMC 5106328. PMID 27454940.
- ↑ 26.0 26.1 Commandeur AE, Styer AK, Teixeira JM (2015). “Epidemiological and genetic clues for molecular mechanisms involved in uterine leiomyoma development and growth”. Hum. Reprod. Update. 21 (5): 593–615. doi:10.1093/humupd/dmv030. PMC 4533663. PMID 26141720.
- ↑ 27.0 27.1 Flake GP, Andersen J, Dixon D (June 2003). “Etiology and pathogenesis of uterine leiomyomas: a review”. Environ. Health Perspect. 111 (8): 1037–54. doi:10.1289/ehp.5787. PMC 1241553. PMID 12826476.
- ↑ 28.0 28.1 Lobel MK, Somasundaram P, Morton CC (March 2006). “The genetic heterogeneity of uterine leiomyomata”. Obstet. Gynecol. Clin. North Am. 33 (1): 13–39. doi:10.1016/j.ogc.2005.12.006. PMID 16504804.
- ↑ 29.0 29.1 Wolańska M, Bańkowski E (February 2007). “Transforming growth factor beta and platelet-derived growth factor in human myometrium and in uterine leiomyomas at various stages of tumour growth”. Eur. J. Obstet. Gynecol. Reprod. Biol. 130 (2): 238–44. doi:10.1016/j.ejogrb.2006.01.034. PMID 16564125.
- ↑ 30.0 30.1 Baird DD, Kesner JS, Dunson DB (February 2006). “Luteinizing hormone in premenopausal women may stimulate uterine leiomyomata development”. J. Soc. Gynecol. Investig. 13 (2): 130–5. doi:10.1016/j.jsgi.2005.12.001. PMID 16443507.
- ↑ 31.0 31.1 Andersen J (August 1996). “Growth factors and cytokines in uterine leiomyomas”. Semin. Reprod. Endocrinol. 14 (3): 269–82. doi:10.1055/s-2007-1016336. PMID 8885057.
- ↑ 32.0 32.1 Laganà AS, Vergara D, Favilli A, La Rosa VL, Tinelli A, Gerli S, Noventa M, Vitagliano A, Triolo O, Rapisarda A, Vitale SG (November 2017). “Epigenetic and genetic landscape of uterine leiomyomas: a current view over a common gynecological disease”. Arch. Gynecol. Obstet. 296 (5): 855–867. doi:10.1007/s00404-017-4515-5. PMID 28875276. Vancouver style error: initials (help)
- ↑ 33.0 33.1 Koutsilieris M (May 1992). “Pathophysiology of uterine leiomyomas”. Biochem. Cell Biol. 70 (5): 273–8. PMID 1323302.
- ↑ 34.0 34.1 Wang TT, Zhang R, Wang L, Chen Y, Dong Q, Li TJ (March 2014). “Two cases of multiple ossifying fibromas in the jaws”. Diagn Pathol. 9: 75. doi:10.1186/1746-1596-9-75. PMC 3974450. PMID 24678936.
- ↑ 35.0 35.1 Chen Y, Hu DY, Wang TT, Zhang R, Dong Q, Xu ZX, Wang L, Li TJ (September 2016). “CDC73 gene mutations in sporadic ossifying fibroma of the jaws”. Diagn Pathol. 11 (1): 91. doi:10.1186/s13000-016-0532-0. PMC 5034632. PMID 27658992.
- ↑ 36.0 36.1 Maria A, Sharma Y, Malik M (December 2013). “Juvenile ossifying fibroma of mandible: a case report”. J Maxillofac Oral Surg. 12 (4): 447–50. doi:10.1007/s12663-010-0122-8. PMID 24431886.
- ↑ 37.0 37.1 Alghonaim Y, ALRashed ALHumaid S, Arafat A (2018). “Aggressive ossifying fibroma of right ethmoidal sinus: A case report”. Int J Surg Case Rep. 53: 513–516. doi:10.1016/j.ijscr.2017.12.026. PMC 6290393. PMID 29373206.
- ↑ 38.0 38.1 Liu Y, Shan XF, Guo XS, Xie S, Cai ZG (2017). “Clinicopathological Characteristics and Prognosis of Ossifying Fibroma in the Jaws of Children: A Retrospective Study”. J Cancer. 8 (17): 3592–3597. doi:10.7150/jca.21556. PMC 5687175. PMID 29151945.
- ↑ 39.0 39.1 Liu JJ, Thompson LD, Janisiewicz AM, Shibuya TY, Keschner DB, Garg R, Lee JT (March 2017). “Ossifying fibroma of the maxilla and sinonasal tract: Case series”. Allergy Rhinol (Providence). 8 (1): 32–36. doi:10.2500/ar.2017.8.0190. PMC 5380450. PMID 28381325.
- ↑ 40.0 40.1 Misra SR, Saigal A, Rastogi V, Priyadarshini SR, Pati AR (January 2015). “Giant central ossifying fibroma of the maxilla presenting with a pus discharging intra-oral sinus”. J Clin Diagn Res. 9 (1): ZD08–11. doi:10.7860/JCDR/2015/11192.5417. PMC 4347180. PMID 25738089.
- ↑ 41.0 41.1 Bowers LM, Cohen DM, Bhattacharyya I, Pettigrew JC, Stavropoulos MF (June 2013). “The non-ossifying fibroma: a case report and review of the literature”. Head Neck Pathol. 7 (2): 203–10. doi:10.1007/s12105-012-0399-7. PMID 23008139.
- ↑ 42.0 42.1 Herget GW, Mauer D, Krauß T, El Tayeh A, Uhl M, Südkamp NP, Hauschild O (April 2016). “Non-ossifying fibroma: natural history with an emphasis on a stage-related growth, fracture risk and the need for follow-up”. BMC Musculoskelet Disord. 17: 147. doi:10.1186/s12891-016-1004-0. PMC 4820930. PMID 27044378.
- ↑ 43.0 43.1 Goldin A, Muzykewicz DA, Dwek J, Mubarak SJ (October 2017). “The aetiology of the non-ossifying fibroma of the distal femur and its relationship to the surrounding soft tissues”. J Child Orthop. 11 (5): 373–379. doi:10.1302/1863-2548.11.170068. PMC 5643931. PMID 29081852.
- ↑ 44.0 44.1 Schneider M, Zimmermann AC, Depprich RA, Kübler NR, Engers R, Naujoks CD, Handschel J (November 2009). “Desmoplastic fibroma of the mandible–review of the literature and presentation of a rare case”. Head Face Med. 5: 25. doi:10.1186/1746-160X-5-25. PMID 19930688.
- ↑ 45.0 45.1 Nedopil A, Raab P, Rudert M (2013). “Desmoplastic fibroma: a case report with three years of clinical and radiographic observation and review of the literature”. Open Orthop J. 8: 40–6. doi:10.2174/1874325001307010040. PMID 23459513.
- ↑ 46.0 46.1 Gong YB, Qu LM, Qi X, Liu JG (October 2015). “Desmoplastic fibroma in the proximal femur: A case report with long-term follow-up”. Oncol Lett. 10 (4): 2465–2467. doi:10.3892/ol.2015.3603. PMID 26622872.
- ↑ 47.0 47.1 Daneyemez M, Akay KM, Izci Y (October 2005). “Desmoplastic fibroma of the cervical spine”. Eur Spine J. 14 (8): 799–802. doi:10.1007/s00586-005-0904-8. PMID 15937674.
- ↑ 48.0 48.1 Woods TR, Cohen DM, Islam MN, Rawal Y, Bhattacharyya I (June 2015). “Desmoplastic fibroma of the mandible: a series of three cases and review of literature”. Head Neck Pathol. 9 (2): 196–204. doi:10.1007/s12105-014-0561-5. PMID 25113037.
- ↑ 49.0 49.1 Goyal T, Rastogi S, Tripathy SK (March 2013). “Desmoplastic fibroma of ulna: Excision and reconstruction of olecranon with a fibular graft”. Indian J Orthop. 47 (2): 207–10. doi:10.4103/0019-5413.108928. PMC 3654474. PMID 23682186.
- ↑ 50.0 50.1 Evans S, Ramasamy A, Jeys L, Grimer R (November 2014). “Desmoplastic fibroma of bone: A rare bone tumour”. J Bone Oncol. 3 (3–4): 77–9. doi:10.1016/j.jbo.2014.08.001. PMC 4723648. PMID 26909301.
- ↑ 51.0 51.1 Aremu AA, Oyedeji OA, Asaleye CM, Adetiloye VA (2013). “An elusive chest coin in an African child: a pleural fibroma’s long, tortuous path to freedom”. Pan Afr Med J. 14: 16. doi:10.11604/pamj.2013.14.16.1874. PMC 3597858. PMID 23503999.
- ↑ 52.0 52.1 Hassan S, Husain SS, Anwar MA, Saeed S (2015). “Pleural Fibroma; A meandering path to surgical removal”. Pak J Med Sci. 31 (1): 236–8. doi:10.12669/pjms.311.5517. PMC 4386196. PMID 25878653.
- ↑ 53.0 53.1 Ali JM, Ali A, Van Leuven M, Bartosik WR (July 2017). “Giant solitary fibrous tumour of the pleura an unpredictable entity: case series and literature review”. Ann R Coll Surg Engl. 99 (6): e165–e171. doi:10.1308/rcsann.2017.0067. PMC 5696978. PMID 28660826.
- ↑ 54.0 54.1 Supakul R, Sodhi A, Tamashiro CY, Azmi SS, Kadaria D (December 2015). “Solitary Fibrous Tumor of the Pleura: A Rare Cause of Pleural Mass”. Am J Case Rep. 16: 854–7. PMC 4671454. PMID 26632548.
- ↑ 55.0 55.1 Guo W, Xiao HL, Jiang YG, Wang RW, Zhao YP, Ma Z, Niu HJ (October 2011). “Retrospective analysis for thirty-nine patients with solitary fibrous tumor of pleura and review of the literature”. World J Surg Oncol. 9: 134. doi:10.1186/1477-7819-9-134. PMC 3214850. PMID 22014289.
- ↑ 56.0 56.1 Chu X, Zhang L, Xue Z, Ren Z, Sun YE, Wang M, Liu M (April 2012). “Solitary fibrous tumor of the pleura: An analysis of forty patients”. J Thorac Dis. 4 (2): 146–54. doi:10.3978/j.issn.2072-1439.2012.01.05. PMID 22833820.
- ↑ 57.0 57.1 Guo J, Chu X, Sun YE, Zhang L, Zhou N (November 2010). “Giant solitary fibrous tumor of the pleura: an analysis of five patients”. World J Surg. 34 (11): 2553–7. doi:10.1007/s00268-010-0715-x. PMC 2949573. PMID 20628740.
- ↑ 58.0 58.1 Moat NE, Teale JD, Lea RE, Matthews AW (December 1991). “Spontaneous hypoglycaemia and pleural fibroma: role of insulin like growth factors”. Thorax. 46 (12): 932–3. doi:10.1136/thx.46.12.932. PMC 463503. PMID 1792644.
- ↑ 59.0 59.1 Masson EA, MacFarlane IA, Graham D, Foy P (December 1991). “Spontaneous hypoglycaemia due to a pleural fibroma: role of insulin like growth factors”. Thorax. 46 (12): 930–1. doi:10.1136/thx.46.12.930. PMID 1792643.
- ↑ 60.0 60.1 Vejvodova S, Spidlen V, Mukensnabl P, Krakorova G, Molacek J, Vodicka J (February 2017). “Solitary Fibrous Tumor – Less Common Neoplasms of the Pleural Cavity”. Ann Thorac Cardiovasc Surg. 23 (1): 12–18. doi:10.5761/atcs.oa.16-00108. PMC 5347482. PMID 28049955.
- ↑ 61.0 61.1 Rahnemai-Azar AA, Rahnemai-Aazr AA, Robinson P, Pham S (July 2013). “Solitary fibrous tumour of the pleura masquerading as catecholamine-secreting paraganglioma”. BMJ Case Rep. 2013. doi:10.1136/bcr-2013-009939. PMC 3736364. PMID 23832995.
- ↑ 62.0 62.1 Ichiki Y, Kakizoe K, Hamatsu T, Matsuyama A, Suehiro T, Tanaka F, Hisaoka M, Sugimachi K (December 2017). “Solitary fibrous tumor of the lung: a case report”. Surg Case Rep. 3 (1): 10. doi:10.1186/s40792-016-0286-7. PMC 5218951. PMID 28063145.
- ↑ 63.0 63.1 Torimitsu S, Nemoto T, Wakayama M, Okubo Y, Yokose T, Kitahara K, Ozawa T, Nakayama H, Shinozaki M, Sasai D, Ishiwatari T, Takuma K, Shibuya K (March 2012). “Literature survey on epidemiology and pathology of cardiac fibroma”. Eur. J. Med. Res. 17: 5. doi:10.1186/2047-783X-17-5. PMC 3351722. PMID 22472419.
- ↑ 64.0 64.1 Jha NK, Kiraly L, Tamas C, Talo H, Khan MD, El Badaoui H, Jain A, Hammad A (March 2015). “Large cardiac fibroma and teratoma in children- case reports”. J Cardiothorac Surg. 10: 38. doi:10.1186/s13019-015-0242-9. PMC 4373309. PMID 25887953.
- ↑ 65.0 65.1 Busch U, Kampmann C, Meyer R, Sandring KH, Hausdorf G, Konertz W (1995). “Removal of a giant cardiac fibroma from a 4-year-old child”. Tex Heart Inst J. 22 (3): 261–4. PMC 325263. PMID 7580366.
- ↑ 66.0 66.1 Bossert T, Walther T, Vondrys D, Gummert JF, Kostelka M, Mohr FW (2006). “Cardiac fibroma as an inherited manifestation of nevoid basal-cell carcinoma syndrome”. Tex Heart Inst J. 33 (1): 88–90. PMC 1413607. PMID 16572881.
- ↑ 67.0 67.1 Heidari A, Sabzi F, Faraji R (2018). “Right atrial fibroma in an adult patient”. Ann Card Anaesth. 21 (1): 65–67. doi:10.4103/aca.ACA_121_17. PMC 5791493. PMID 29336396.
- ↑ 68.0 68.1 Scanlan D, Radio SJ, Nelson M, Zhou M, Streblow R, Prasad V, Reyes C, Perry D, Fletcher S, Bridge JA (2008). “Loss of the PTCH1 gene locus in cardiac fibroma”. Cardiovasc. Pathol. 17 (2): 93–7. doi:10.1016/j.carpath.2007.08.001. PMC 2342874. PMID 18329553.
- ↑ 69.0 69.1 Ying L, Lin R, Gao Z, Qi J, Zhang Z, Gu W (April 2016). “Primary cardiac tumors in children: a center’s experience”. J Cardiothorac Surg. 11 (1): 52. doi:10.1186/s13019-016-0448-5. PMID 27067427.
- ↑ 70.0 70.1 Yadava OP (2012). “Cardiac tumours in infancy”. Indian Heart J. 64 (5): 492–6. doi:10.1016/j.ihj.2012.05.004. PMC 3861228. PMID 23102388.
- ↑ 71.0 71.1 Cho SH, Fritz T, Cronin LJ, Cohle SD (2015). “Primary Cardiac Fibroma in an Adult”. Case Rep Cardiol. 2015: 713702. doi:10.1155/2015/713702. PMID 26457206.
- ↑ 72.0 72.1 Mecchia D, Lavezzi AM, Matturri L (2013). “Primary Cardiac Fibroma and Cardiac Conduction System Alterations in a Case of Sudden Death of a 4-month-old Infant”. Open Cardiovasc Med J. 7: 47–9. doi:10.2174/1874192401307010047. PMC 3706798. PMID 23847693.
- ↑ 73.0 73.1 Kumar S, Choudhary GR, Nanjappa B, Bal A (2013). “Benign medullary fibroma of the kidney: a rare diagnostic dilemma”. J Clin Imaging Sci. 3: 43. doi:10.4103/2156-7514.120776. PMC 3823390. PMID 24228211.
- ↑ 74.0 74.1 Bircan S, Orhan D, Tulunay O, Safak M (2000). “Renomedullary interstitial cell tumor”. Urol. Int. 65 (3): 163–6. doi:10.1159/000064864. PMID 11054036.
- ↑ 75.0 75.1 Bazzi WM, Huang H, Al-Ahmadie H, Russo P (May 2014). “Clinicopathologic features of renomedullary interstitial cell tumor presenting as the main solid renal mass”. Urology. 83 (5): 1104–6. doi:10.1016/j.urology.2014.01.008. PMID 24642074.
- ↑ 76.0 76.1 Bala TK, Soni S, Dayal P, Ghosh I (May 2017). “Cemento-ossifying fibroma of the mandible. A clinicopathological report”. Saudi Med J. 38 (5): 541–545. doi:10.15537/smj.2017.5.15643. PMC 5447217. PMID 28439606.
- ↑ 77.0 77.1 Chatterjee A, Ajmera N, Singh A (July 2010). “Peripheral cemento-ossifying fibroma of maxilla”. J Indian Soc Periodontol. 14 (3): 186–9. doi:10.4103/0972-124X.75915. PMC 3100863. PMID 21760674.
- ↑ 78.0 78.1 Mishra AK, Maru R, Dhodapkar SV, Jaiswal G, Kumar R, Punjabi H (June 2013). “Peripheral cemento-ossifying fibroma: A case report with review of literature”. World J Clin Cases. 1 (3): 128–33. doi:10.12998/wjcc.v1.i3.128. PMC 3845913. PMID 24303483.
- ↑ 79.0 79.1 Dalghous A, Alkhabuli JO (June 2007). “Cemento-ossifying fibroma occurring in an elderly patient. A case report and a review of literature”. Libyan J Med. 2 (2): 95–8. doi:10.4176/061220. PMC 3078280. PMID 21503260.
- ↑ 80.0 80.1 Hekmatnia A, Ghazavi A, Saboori M, Mahzouni P, Tayari N, Hekmatnia F (February 2011). “A case report of cemento-ossifying fibroma presenting as a mass of the ethmoid sinus”. J Res Med Sci. 16 (2): 224–8. PMC 3214308. PMID 22091236.
- ↑ 81.0 81.1 Katti G, Khan MM, Chaubey SS, Amena M (May 2016). “Cemento-ossifying fibroma of the jaw”. BMJ Case Rep. 2016. doi:10.1136/bcr-2015-214327. PMC 4885328. PMID 27174452.
- ↑ 82.0 82.1 Ram R, Singhal A, Singhal P (January 2012). “Cemento-ossifying fibroma”. Contemp Clin Dent. 3 (1): 83–5. doi:10.4103/0976-237X.94553. PMC 3341766. PMID 22557904.
- ↑ 83.0 83.1 Sah K, Kale AD, Hallikerimath S, Chandra S (April 2012). “Peripheral cemento-ossifying fibroma: Report of a recurrence case”. Contemp Clin Dent. 3 (Suppl 1): S23–5. doi:10.4103/0976-237X.95098. PMC 3354807. PMID 22629060.
- ↑ 84.0 84.1 Naik RM, Guruprasad Y, Sujatha D, Gurudath S, Pai A, Suresh K (January 2014). “Giant cemento-ossifying fibroma of the mandible”. J Nat Sci Biol Med. 5 (1): 190–4. doi:10.4103/0976-9668.127326. PMC 3961933. PMID 24678226.
- ↑ 85.0 85.1 Pereira, Thaís dos Santos Fontes; Diniz, Marina Gonçalves; França, Josiane Alves; Moreira, Rennan Garcias; Menezes, Grazielle Helena Ferreira de; Sousa, Sílvia Ferreira de; Castro, Wagner Henriques de; Gomes, Carolina Cavaliéri; Gomez, Ricardo Santiago (2018). “The Wnt/β-catenin pathway is deregulated in cemento-ossifying fibromas”. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. 125 (2): 172–178. doi:10.1016/j.oooo.2017.10.004. ISSN 2212-4403.
- ↑ 86.0 86.1 de Sousa SF, Caldeira PC, Grossmann Sde M, de Aguiar MC, Mesquita RA (June 2011). “Desmoplastic fibroblastoma (collagenous fibroma): a case identified in the buccal mucosa”. Head Neck Pathol. 5 (2): 175–9. doi:10.1007/s12105-010-0239-6. PMID 21221866.
- ↑ 87.0 87.1 Pereira TD, de Lacerda JC, Porto-Matias MD, de Jesus AO, Gomez RS, Mesquita RA (February 2016). “Desmoplastic fibroblastoma (collagenous fibroma) of the oral cavity”. J Clin Exp Dent. 8 (1): e89–92. doi:10.4317/jced.52605. PMID 26855713.
- ↑ 88.0 88.1 Grewal R, Natter P, Makary R, Silliman J (January 2018). “Desmoplastic fibroblastoma of the left upper arm”. BMJ Case Rep. 2018. doi:10.1136/bcr-2017-221738. PMID 29374633.
- ↑ 89.0 89.1 Osipov V, Carrera GF (2009). “Collagenous fibroma (desmoplastic fibroblastoma) with vertebral body erosion”. Sarcoma. 2009: 682687. doi:10.1155/2009/682687. PMID 19503798.
- ↑ 90.0 90.1 Nagaraja V, Coleman HG, Morgan GJ (September 2013). “Desmoplastic fibroblastoma presenting as a parotid tumour: a case report and review of the literature”. Head Neck Pathol. 7 (3): 285–90. doi:10.1007/s12105-013-0435-2. PMC 3738752. PMID 23504494.
- ↑ 91.0 91.1 Kim JH, Oh DY, Kim SW, Lee JH, Ahn ST, Rhie JW (January 2012). “Desmoplastic fibroblastoma of the finger tip in an adult”. Arch Plast Surg. 39 (1): 84–6. doi:10.5999/aps.2012.39.1.84. PMC 3385291. PMID 22783503.
- ↑ 92.0 92.1 Darling MR, Kutalowski M, MacPherson DG, Jackson-Boeters L, Wysocki GP (September 2011). “Oral elastofibromatous lesions: a review and case series”. Head Neck Pathol. 5 (3): 254–8. doi:10.1007/s12105-011-0274-y. PMC 3173539. PMID 21681661.
- ↑ 93.0 93.1 Daum O, Ferda J, Curik R, Choc M, Mukensnabl P, Michal M (December 2010). “Elastofibromatous changes in tissues from spinal biopsies. A degenerative process afflicting a small but important subset of patients operated for spinal canal compression: report of 18 cases”. Int. J. Surg. Pathol. 18 (6): 508–15. doi:10.1177/1066896909339736. PMID 19578045.
- ↑ 94.0 94.1 Tosios KI, Economou I, Vasilopoulos NN, Koutlas IG (March 2010). “Elastofibromatous changes and hyperelastosis of the oral mucosa”. Head Neck Pathol. 4 (1): 31–6. doi:10.1007/s12105-009-0153-y. PMC 2825534. PMID 20237986.
- ↑ 95.0 95.1 Smith HG, Hannay JA, Thway K, Messiou C, Smith MJ, Strauss DC, Hayes AJ (March 2016). “Elastofibroma dorsi: The clunking tumour that need not cause alarm”. Ann R Coll Surg Engl. 98 (3): 208–11. doi:10.1308/rcsann.2016.0064. PMC 5226161. PMID 26890837.
- ↑ 96.0 96.1 Kourda J, Ayadi-Kaddour A, Merai S, Hantous S, Miled KB, Mezni FE (September 2009). “Bilateral elastofibroma dorsi. A case report and review of the literature”. Orthop Traumatol Surg Res. 95 (5): 383–7. doi:10.1016/j.otsr.2009.05.002. PMID 19628444.
- ↑ 97.0 97.1 Hoven-Gondrie ML, IJpma FF, Havenith MG, van Geldere D (2009). “[Elastofibroma dorsi: a characteristic, benign, subscapular swelling]”. Ned Tijdschr Geneeskd (in Dutch; Flemish). 153: A569. PMID 19900325.
- ↑ 98.0 98.1 Hayes AJ, Alexander N, Clark MA, Thomas JM (May 2004). “Elastofibroma: a rare soft tissue tumour with a pathognomonic anatomical location and clinical symptom”. Eur J Surg Oncol. 30 (4): 450–3. doi:10.1016/j.ejso.2004.01.006. PMID 15063901.
- ↑ 99.0 99.1 Bhambri A, Del Rosso JQ (June 2009). “Solitary sclerotic fibroma”. J Clin Aesthet Dermatol. 2 (6): 36–8. PMC 2923956. PMID 20729948.
- ↑ 100.0 100.1 Nakashima K, Yamada N, Adachi K, Yoshida Y, Yamamoto O (October 2008). “Solitary sclerotic fibroma of the skin: morphological characterization of the ‘plywood-like pattern‘“. J. Cutan. Pathol. 35 Suppl 1: 74–9. doi:10.1111/j.1600-0560.2008.01001.x. PMID 18544068.
- ↑ 101.0 101.1 Requena L, Gutiérrez J, Sánchez Yus E (August 1992). “Multiple sclerotic fibromas of the skin. A cutaneous marker of Cowden’s disease”. J. Cutan. Pathol. 19 (4): 346–51. PMID 1430474.
- ↑ 102.0 102.1 Mori O, Hachisuka H, Sasai Y (1992). “Sclerotic fibromas of the skin–reports of two cases and a review of the literature in Japan”. Kurume Med J. 39 (3): 191–3. PMID 1491554.
- ↑ 103.0 103.1 Lo WL, Wong CK (October 1990). “Solitary sclerotic fibroma”. J. Cutan. Pathol. 17 (5): 269–73. PMID 2258475.
- ↑ 104.0 104.1 Hanft VN, Shea CR, McNutt NS, Pullitzer D, Horenstein MG, Prieto VG (February 2000). “Expression of CD34 in sclerotic (“plywood”) fibromas”. Am J Dermatopathol. 22 (1): 17–21. PMID 10698210.
- ↑ 105.0 105.1 High WA, Stewart D, Essary LR, Kageyama NP, Hoang MP, Cockerell CJ (May 2004). “Sclerotic fibroma-like change in various neoplastic and inflammatory skin lesions: is sclerotic fibroma a distinct entity?”. J. Cutan. Pathol. 31 (5): 373–8. doi:10.1111/j.0303-6987.2004.00199.x. PMID 15059222.
- ↑ 106.0 106.1 Shitabata PK, Crouch EC, Fitzgibbon JF, Swanson PE, Adesokan PN, Wick MR (August 1995). “Cutaneous sclerotic fibroma. Immunohistochemical evidence of a fibroblastic neoplasm with ongoing type I collagen synthesis”. Am J Dermatopathol. 17 (4): 339–43. PMID 8600796.
- ↑ 107.0 107.1 Alawi F, Freedman PD (June 2004). “Sporadic sclerotic fibroma of the oral soft tissues”. Am J Dermatopathol. 26 (3): 182–7. PMID 15166503.
- ↑ 108.0 108.1 Upadhyaya JD, Cohen DM, Islam MN, Bhattacharyya I (June 2018). “Hybrid Central Odontogenic Fibroma with Giant Cell Granuloma like Lesion: A Report of Three Additional Cases and Review of the Literature”. Head Neck Pathol. 12 (2): 166–174. doi:10.1007/s12105-017-0845-7. PMC 5953869. PMID 28785965.
- ↑ 109.0 109.1 Sonalika WG, Sahu A, Deogade SC, Gupta P, Naitam D, Chansoria H, Agarwal J, Katoch S (2014). “Giant cell fibroma of tongue: understanding the nature of an unusual histopathological entity”. Case Rep Dent. 2014: 864512. doi:10.1155/2014/864512. PMC 3910466. PMID 24511398.
- ↑ 110.0 110.1 Tosios KI, Gopalakrishnan R, Koutlas IG (December 2008). “So-called hybrid central odontogenic fibroma/central giant cell lesion of the jaws. A report on seven additional cases, including an example in a patient with cherubism, and hypotheses on the pathogenesis”. Head Neck Pathol. 2 (4): 333–8. doi:10.1007/s12105-008-0076-z. PMC 2807578. PMID 20614305.
- ↑ 111.0 111.1 Sabarinath B, Sivaramakrishnan M, Sivapathasundharam B (September 2012). “Giant cell fibroma: A clinicopathological study”. J Oral Maxillofac Pathol. 16 (3): 359–62. doi:10.4103/0973-029X.102485. PMC 3519210. PMID 23248467.
- ↑ 112.0 112.1 Mello-Moura AC, Santos AM, Bonini GA, Del Conte Zardetto CG, Moura-Netto C, Wanderley MT (2016). “Giant Cell Fibroma in a Two-Year-Old Child”. Case Rep Dent. 2016: 7058356. doi:10.1155/2016/7058356. PMC 5086372. PMID 27822394.
- ↑ 113.0 113.1 Hosur MB, Puranik RS, Vanaki SS, Puranik SR, Ingaleshwar PS (2018). “Clinicopathological profile of central giant cell granulomas: An institutional experience and study of immunohistochemistry expression of p63 in central giant cell granuloma”. J Oral Maxillofac Pathol. 22 (2): 173–179. doi:10.4103/jomfp.JOMFP_260_17. PMC 6097366. PMID 30158768.
- ↑ 114.0 114.1 Kulkarni S, Chandrashekar C, Kudva R, Radhakrishnan R (2017). “Giant-cell fibroma: Understanding the nature of the melanin-laden cells”. J Oral Maxillofac Pathol. 21 (3): 429–433. doi:10.4103/jomfp.JOMFP_209_16. PMC 5763868. PMID 29391720.
- ↑ 115.0 115.1 Jimson S, Jimson S (December 2013). “Giant cell fibroma: a case report with immunohistochemical markers”. J Clin Diagn Res. 7 (12): 3079–80. doi:10.7860/JCDR/2013/6476.3859. PMC 3919395. PMID 24551733.
- ↑ 116.0 116.1 Chandna P, Srivastava N, Bansal V, Wadhwan V, Dubey P (2017). “Peripheral and Central Giant Cell Lesions in Children: Institutional Experience at Subharti Dental College and Hospital”. Indian J Med Paediatr Oncol. 38 (4): 440–446. doi:10.4103/ijmpo.ijmpo_17_16. PMC 5759061. PMID 29333009.
- ↑ 117.0 117.1 Wright JM, Soluk Tekkesin M (2017). “Odontogenic tumors: where are we in 2017 ?”. J Istanb Univ Fac Dent. 51 (3 Suppl 1): S10–S30. doi:10.17096/jiufd.52886. PMC 5750825. PMID 29354306.
- ↑ 118.0 118.1 Reddy SV, Medikonda SK, Konda A, Natta S (June 2014). “A rare benign odontogenic neoplasm: peripheral odontogenic fibroma”. BMJ Case Rep. 2014. doi:10.1136/bcr-2013-201065. PMC 4069815. PMID 24920510.
- ↑ 119.0 119.1 Baiju CS, Rohatgi S (July 2011). “Peripheral odontogenic fibroma: A case report and review”. J Indian Soc Periodontol. 15 (3): 273–5. doi:10.4103/0972-124X.85674. PMC 3200026. PMID 22028517.
- ↑ 120.0 120.1 Sreeja C, Vezhavendan N, Shabana F, Vijayalakshmi D, Devi M, Arunakiry N (July 2014). “Recurrent peripheral odontogenic fibroma associated with basal cell budding”. J Pharm Bioallied Sci. 6 (Suppl 1): S204–7. doi:10.4103/0975-7406.137470. PMC 4157271. PMID 25210375.
Causes
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Maneesha Nandimandalam, M.B.B.S.[2], Simrat Sarai, M.D. [3]
Overview
Common causes of oral fibroma include trauma or chronic irritation. There are no established causes for chondromyxoid fibroma, non-ossifying fibroma, cemento-ossifying fibroma, and ossifying fibroma. Although there are some associated factors for the development of some fibromas like ovarian fibroma, uterine fibroma.
Causes
| Type of fibroma | Causes/ associated factors |
|---|---|
| Ovarian Fibroma[1][2] | |
| Non-ossifying Fibroma [3][4] | Clonal rearrangements in chromosomes 1, 3, 4, 11, and 14 |
| Uterine Fibroma [5] | Genetic changes
|
| Oral Fibroma | Trauma or chronic irritation |
| Chondromyxoid Fibroma [6][7] | Clonal rearrangement of chromosome 6 |
References
- ↑ Boujoual M, Hakimi I, Kouach J, Oukabli M, Moussaoui DR, Dehayni M (2015). “Large twisted ovarian fibroma in menopausal women: a case report”. Pan Afr Med J. 20: 322. doi:10.11604/pamj.2015.20.322.5998. PMC 4491469. PMID 26175813.
- ↑ Chen H, Liu Y, Shen LF, Jiang MJ, Yang ZF, Fang GP (November 2016). “Ovarian thecoma-fibroma groups: clinical and sonographic features with pathological comparison”. J Ovarian Res. 9 (1): 81. doi:10.1186/s13048-016-0291-2. PMC 5120502. PMID 27876070.
- ↑ Bowers LM, Cohen DM, Bhattacharyya I, Pettigrew JC, Stavropoulos MF (June 2013). “The non-ossifying fibroma: a case report and review of the literature”. Head Neck Pathol. 7 (2): 203–10. doi:10.1007/s12105-012-0399-7. PMID 23008139.
- ↑ Herget GW, Mauer D, Krauß T, El Tayeh A, Uhl M, Südkamp NP, Hauschild O (April 2016). “Non-ossifying fibroma: natural history with an emphasis on a stage-related growth, fracture risk and the need for follow-up”. BMC Musculoskelet Disord. 17: 147. doi:10.1186/s12891-016-1004-0. PMC 4820930. PMID 27044378.
- ↑ Okolo S (August 2008). “Incidence, aetiology and epidemiology of uterine fibroids”. Best Pract Res Clin Obstet Gynaecol. 22 (4): 571–88. doi:10.1016/j.bpobgyn.2008.04.002. PMID 18534913.
- ↑ Takenaga RK, Frassica FJ, McCarthy EF (2007). “Subperiosteal chondromyxoid fibroma: a report of two cases”. Iowa Orthop J. 27: 104–7. PMC 2150655. PMID 17907440.
- ↑ Sharma H, Jane MJ, Reid R (June 2006). “Chondromyxoid fibroma of the foot and ankle: 40 years’ Scottish bone tumour registry experience”. Int Orthop. 30 (3): 205–9. doi:10.1007/s00264-005-0046-y. PMC 2532097. PMID 16547720.
Epidemiology and Demographics
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Maneesha Nandimandalam, M.B.B.S.[2], Simrat Sarai, M.D. [3]
Overview
Patients of all age groups may develop fibromas. However, the majority of fibromas are observed in adults. Fibromas usually affects men and women equally, however certain fibromas may show gender predilection. Fibromas are most often observed in adults, but they may occur in individuals of any age and either sex.
Epidemiology and Demographics
Non-ossifying Fibroma
Prevalence
The prevalence of non-ossifying fibroma is estimated to be 30-40 % of all normal children.
Age
Non-ossifying fibromas are the most common fibrous bony lesions in children and adolescents, with a peak incidence at 10-15 years old. Non-ossifying fibromas are not seen beyond the age of 30 years, as they spontaneously heal. The age of presentation of the isolated mandibular non-ossifying fibroma appears to differ from that of the long bones in that the mandibular NOF appears at an older average age at diagnosis. The overall incidence of non-ossifying fibromas in the long bones is 30–40 % of children over the age of 2 with the highest incidence between ages 4 and 8 years.
Gender
Males are more commonly affected with non-ossifying fibromas of the long bones than females. The male to female ratio is approximately 2 to 1. Females are more commonly affected with mandibular NOF than males.
Desmoplastic Fibroma
Incidence
The incidence of desmoplastic fibroma is approximately 0.11% of all primary bone tumors.[1][2]
Age
The median age at presentation is 21 years.
Gender
Desmoplastic fibromas affects men and women equally.
Ovarian Fibroma
Ovarian fibromas represent 4% of all ovarian neoplasms. They tend to occur mostly during perimenopause and postmenopause.[3][4][5]
Age
Patients of all age groups may develop ovarian fibroma. However, they are most frequently seen in middle-aged women. The median age at diagnosis is 52 years. Ovarian fibromas commonly affects individuals during perimenopause and postmenopause. They are rare in children.
Ossifying Fibroma
Age
Ossifying fibromas most frequently occur in young children (less than 10 years of age). The median age at diagnosis for females and for males is 13 years and 10 years respectively.[6][7]
Gender
Ossifying fibromas affects men and women equally.
Chondromyxoid Fibroma
A chondromyxoid fibroma (CMF) is an extremely rare benign cartilaginous neoplasm which accounts for < 1% bone tumours.[8][9][10]
Gender
Chondromyxoid fibromas affects men and women equally.
Age
Patients of all age groups may develop chondromyxoid fibroma. However, they are most frequently seen in second and third decades. Approximately 75% of cases occur before the age of 30 years. The location of chondromyxoid fibroma(CMF) varies with age. It is found predominantly in long bones between 1 and 10 years, while the distribution of localization becomes equal between the long bones, flat bones and ribs in the fourth decade. According to some authors, the average age for intracranial CMF is 37 – 39 years. It is 32.7years (range 15-50 years) among patients who have frontal CMF.The duration of the symptoms before diagnosis varies between 10 days and 20 years.[11]
Cardiac Fibroma
Age
Cardiac fibromas primarily affects children, the majority of cases are detected in infants or in utero. They are the second most common benign primary cardiac tumour in children after cardiac rhabdomyoma and second commonest fetal cardiac tumor.[12]
Pleural Fibromas
Gender
Pleural fibromas affects men and women equally.[13][14]
Age
Pleural fibromas usually presents in the 6th to 7th decades.
Cemento-ossifying Fibroma
Age
Cemento-ossifying fibromas are most frequently diagnosed during the third and fourth decades. Occasionally, they are identified in children, in which case they are a more aggressive variant and are known as juvenile aggressive cemento-ossifying fibromas. Patients of all age groups may develop cemento-ossifying fibroma. Cemento-ossifying fibroma commonly affects individuals 10-20 years of age.[15][16][17][18]
Gender
Females are more commonly affected with cemento-ossifying fibromas than males. The female to male ratio is approximately 3 to 2.
Oral Fibroma
Oral fibromas are the most common oral cavity tumors.[19]
Age
Patients of all age groups may develop oral fibromas. However, they are most commonly seen in older adults, usually 30-50 years old. It affects 1-2% of adults. It is the most common oral cavity tumour.
Gender
Females are more commonly affected with oral fibromas than males. The female to male ratio is approximately 2 to 1.
Giant cell fibroma
Age
Patients of all age groups may develop giant cell fibroma. The majority of cases of giant cell fibroma are diagnosed in persons aged 10-30 years.[20][21][22][23]
Gender
Giant cell fibromas affects men and women equally.
Elastofibroma
Age
Elastofibroma commonly affects individuals older than 50 years of age. Elastofibroma is a rare disease that tends to affect elderly population (< 0.001% of soft tissue tumors).[24][25]
Gender
Females are more commonly affected with elastofibroma than males. The female to male ratio is approximately 5 to 1.
Uterine Fibroma
Age
Uterine fibromas occur in approximately 25% of women of reproductive age. Approximately 40% of women by age 40 years develop uterine fibromas. Uterine fibromas commonly affects females after puberty, they commonly accelerate in growth during pregnancy and involute with menopause. Uterine fibromas commonly affects individuals older than 30 years of age. Approximately 20% to 80% of women develop fibroids by the age of 50.[26][27][28][29][30]
Prevalence
In 2013, it was estimated that 171 million women were affected by uterine fibromas worldwide.[31][32][33][34]
Race
Uterine fibromas usually affects individuals of the African race. Caucasian females are less likely to develop uterine fibromas. African American women are two to three times more likely to get fibroids than Caucasian women. In African-American women fibroids seem to occur at a younger age, grow more quickly, and are more likely to cause symptoms.According to the National Institute of Environmental Health Sciences, eighty percent of African American women will develop benign uterine fibroid tumors by their late 40s.[35][36][37]
Peripheral Odontogenic Fibroma
It is a rare lesion
Age
Patients of all age groups may develop peripheral odontogenic fibroma. Peripheral odontogenic fibroma commonly affects individuals ranged from 5 to 65 years of age.[38][39][40]
Gender
Peripheral odontogenic fibromas affects men and women equally.
References
- ↑ Pereira TD, de Lacerda JC, Porto-Matias MD, de Jesus AO, Gomez RS, Mesquita RA (February 2016). “Desmoplastic fibroblastoma (collagenous fibroma) of the oral cavity”. J Clin Exp Dent. 8 (1): e89–92. doi:10.4317/jced.52605. PMC 4739375. PMID 26855713.
- ↑ Vasconcelos AC, Gomes AP, Tarquinio S, Abduch-Rodrigues E, Mesquita R, Silva K (January 2018). “Oral Bilateral Collagenous Fibroma: A previously unreported case and literature review”. J Clin Exp Dent. 10 (1): e96–e99. doi:10.4317/jced.54123. PMC 5899808. PMID 29670724.
- ↑ Boujoual M, Hakimi I, Kouach J, Oukabli M, Moussaoui DR, Dehayni M (2015). “Large twisted ovarian fibroma in menopausal women: a case report”. Pan Afr Med J. 20: 322. doi:10.11604/pamj.2015.20.322.5998. PMC 4491469. PMID 26175813.
- ↑ Leung SW, Yuen PM (2006). “Ovarian fibroma: a review on the clinical characteristics, diagnostic difficulties, and management options of 23 cases”. Gynecol. Obstet. Invest. 62 (1): 1–6. doi:10.1159/000091679. PMID 16498263.
- ↑ Rajabi P, Hani M, Bagheri M, Mirzadeh F (2014). “Large ovarian leiomyoma in young woman”. Adv Biomed Res. 3: 88. doi:10.4103/2277-9175.128001. PMC 3988605. PMID 24761396.
- ↑ Maria A, Sharma Y, Malik M (December 2013). “Juvenile ossifying fibroma of mandible: a case report”. J Maxillofac Oral Surg. 12 (4): 447–50. doi:10.1007/s12663-010-0122-8. PMC 3847010. PMID 24431886.
- ↑ Alghonaim Y, ALRashed ALHumaid S, Arafat A (2018). “Aggressive ossifying fibroma of right ethmoidal sinus: A case report”. Int J Surg Case Rep. 53: 513–516. doi:10.1016/j.ijscr.2017.12.026. PMC 6290393. PMID 29373206.
- ↑ Sono T, Ware AD, McCarthy EF, James AW (June 2019). “Chondromyxoid Fibroma of the Pelvis: Institutional Case Series With a Focus on Distinctive Features”. Int. J. Surg. Pathol. 27 (4): 352–359. doi:10.1177/1066896918820446. PMC 6504570 Check
|pmc=value (help). PMID 30580642. - ↑ Chowdary PB, Patil MD, Govindarajan AK (July 2015). “Chondromyxoid Fibroma: An Unusual Tumour at An Atypical Location”. J Clin Diagn Res. 9 (7): XD04–XD05. doi:10.7860/JCDR/2015/13134.6184. PMID 26393192.
- ↑ Takenaga RK, Frassica FJ, McCarthy EF (2007). “Subperiosteal chondromyxoid fibroma: a report of two cases”. Iowa Orthop J. 27: 104–7. PMC 2150655. PMID 17907440.
- ↑ Yerleflen, Frontal Kemikte. “Chondromyxoid fibroma of frontal bone: a case report and review of the literature.” Turkish neurosurgery 18.3 (2008): 249-253.
- ↑ Torimitsu S, Nemoto T, Wakayama M, Okubo Y, Yokose T, Kitahara K, Ozawa T, Nakayama H, Shinozaki M, Sasai D, Ishiwatari T, Takuma K, Shibuya K (March 2012). “Literature survey on epidemiology and pathology of cardiac fibroma”. Eur. J. Med. Res. 17: 5. doi:10.1186/2047-783X-17-5. PMC 3351722. PMID 22472419.
- ↑ Hassan S, Husain SS, Anwar MA, Saeed S (2015). “Pleural Fibroma; A meandering path to surgical removal”. Pak J Med Sci. 31 (1): 236–8. doi:10.12669/pjms.311.5517. PMC 4386196. PMID 25878653.
- ↑ Masson EA, MacFarlane IA, Graham D, Foy P (December 1991). “Spontaneous hypoglycaemia due to a pleural fibroma: role of insulin like growth factors”. Thorax. 46 (12): 930–1. doi:10.1136/thx.46.12.930. PMC 463502. PMID 1792643.
- ↑ Verma E, Chakki AB, Nagaral SC, Ganji KK (2013). “Peripheral cemento-ossifying fibroma: case series literature review”. Case Rep Dent. 2013: 930870. doi:10.1155/2013/930870. PMC 3556846. PMID 23365762.
- ↑ Naik RM, Guruprasad Y, Sujatha D, Gurudath S, Pai A, Suresh K (January 2014). “Giant cemento-ossifying fibroma of the mandible”. J Nat Sci Biol Med. 5 (1): 190–4. doi:10.4103/0976-9668.127326. PMC 3961933. PMID 24678226.
- ↑ Katti G, Khan MM, Chaubey SS, Amena M (May 2016). “Cemento-ossifying fibroma of the jaw”. BMJ Case Rep. 2016. doi:10.1136/bcr-2015-214327. PMC 4885328. PMID 27174452.
- ↑ Shejbal D, Vonsović G, Baudoin T, Vagic D (June 2015). “Cystic Shape Cemento-Ossifying Fibroma of Ethmoid Sinus”. Acta Stomatol Croat. 49 (2): 158–211. doi:10.15644/asc49/2/10. PMC 4988820. PMID 27688399.
- ↑ Panta P (2015). “Traumatic fibroma”. Pan Afr Med J. 21: 220. doi:10.11604/pamj.2015.21.220.7498. PMC 4587079. PMID 26448815.
- ↑ Sonalika WG, Sahu A, Deogade SC, Gupta P, Naitam D, Chansoria H, Agarwal J, Katoch S (2014). “Giant cell fibroma of tongue: understanding the nature of an unusual histopathological entity”. Case Rep Dent. 2014: 864512. doi:10.1155/2014/864512. PMC 3910466. PMID 24511398.
- ↑ Sabarinath B, Sivaramakrishnan M, Sivapathasundharam B (September 2012). “Giant cell fibroma: A clinicopathological study”. J Oral Maxillofac Pathol. 16 (3): 359–62. doi:10.4103/0973-029X.102485. PMC 3519210. PMID 23248467.
- ↑ Kulkarni S, Chandrashekar C, Kudva R, Radhakrishnan R (2017). “Giant-cell fibroma: Understanding the nature of the melanin-laden cells”. J Oral Maxillofac Pathol. 21 (3): 429–433. doi:10.4103/jomfp.JOMFP_209_16. PMC 5763868. PMID 29391720.
- ↑ Nikitakis NG, Emmanouil D, Maroulakos MP, Angelopoulou MV (2013). “Giant cell fibroma in children: report of two cases and literature review”. J Oral Maxillofac Res. 4 (1): e5. doi:10.5037/jomr.2013.4105. PMC 3886105. PMID 24422028.
- ↑ Manchandu R, Foote J, Alawi F (2008). “Elastofibroma presenting as an oral soft tissue mass”. J Oral Pathol Med. 37 (2): 125–6. doi:10.1111/j.1600-0714.2007.00592.x. PMID 18197858.
- ↑ Potter TJ, Summerlin DJ, Rodgers SF (2004). “Elastofibroma: the initial report in the oral mucosa”. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 97 (1): 64–7. doi:10.1016/S1079210403005596. PMID 14716258.
- ↑ Zimmermann A, Bernuit D, Gerlinger C, Schaefers M, Geppert K (March 2012). “Prevalence, symptoms and management of uterine fibroids: an international internet-based survey of 21,746 women”. BMC Womens Health. 12: 6. doi:10.1186/1472-6874-12-6. PMC 3342149. PMID 22448610.
- ↑ Wise LA, Laughlin-Tommaso SK (March 2016). “Epidemiology of Uterine Fibroids: From Menarche to Menopause”. Clin Obstet Gynecol. 59 (1): 2–24. doi:10.1097/GRF.0000000000000164. PMC 4733579. PMID 26744813.
- ↑ Wise LA, Palmer JR, Stewart EA, Rosenberg L (March 2005). “Age-specific incidence rates for self-reported uterine leiomyomata in the Black Women’s Health Study”. Obstet Gynecol. 105 (3): 563–8. doi:10.1097/01.AOG.0000154161.03418.e3. PMC 1847590. PMID 15738025.
- ↑ Marshall LM, Spiegelman D, Barbieri RL, Goldman MB, Manson JE, Colditz GA, Willett WC, Hunter DJ (December 1997). “Variation in the incidence of uterine leiomyoma among premenopausal women by age and race”. Obstet Gynecol. 90 (6): 967–73. PMID 9397113.
- ↑ Okolo S (August 2008). “Incidence, aetiology and epidemiology of uterine fibroids”. Best Pract Res Clin Obstet Gynaecol. 22 (4): 571–88. doi:10.1016/j.bpobgyn.2008.04.002. PMID 18534913.
- ↑ Commandeur AE, Styer AK, Teixeira JM (2015). “Epidemiological and genetic clues for molecular mechanisms involved in uterine leiomyoma development and growth”. Hum. Reprod. Update. 21 (5): 593–615. doi:10.1093/humupd/dmv030. PMC 4533663. PMID 26141720.
- ↑ Laughlin SK, Schroeder JC, Baird DD (May 2010). “New directions in the epidemiology of uterine fibroids”. Semin. Reprod. Med. 28 (3): 204–17. doi:10.1055/s-0030-1251477. PMC 5330647. PMID 20414843.
- ↑ Egbe TO, Badjang TG, Tchounzou R, Egbe EN, Ngowe MN (December 2018). “Uterine fibroids in pregnancy: prevalence, clinical presentation, associated factors and outcomes at the Limbe and Buea Regional Hospitals, Cameroon: a cross-sectional study”. BMC Res Notes. 11 (1): 889. doi:10.1186/s13104-018-4007-0. PMC 6293543. PMID 30545402.
- ↑ Fuldeore MJ, Soliman AM (2017). “Patient-reported prevalence and symptomatic burden of uterine fibroids among women in the United States: findings from a cross-sectional survey analysis”. Int J Womens Health. 9: 403–411. doi:10.2147/IJWH.S133212. PMC 5476627. PMID 28652819.
- ↑ Moore KR, Smith JS, Laughlin-Tommaso SK, Baird DD (January 2014). “Cervical neoplasia-related factors and decreased prevalence of uterine fibroids among a cohort of African American women”. Fertil. Steril. 101 (1): 208–14. doi:10.1016/j.fertnstert.2013.09.021. PMC 3880401. PMID 24268705.
- ↑ Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM (January 2003). “High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence”. Am. J. Obstet. Gynecol. 188 (1): 100–7. PMID 12548202.
- ↑ Kjerulff KH, Langenberg P, Seidman JD, Stolley PD, Guzinski GM (July 1996). “Uterine leiomyomas. Racial differences in severity, symptoms and age at diagnosis”. J Reprod Med. 41 (7): 483–90. PMID 8829060.
- ↑ Reddy SV, Medikonda SK, Konda A, Natta S (June 2014). “A rare benign odontogenic neoplasm: peripheral odontogenic fibroma”. BMJ Case Rep. 2014. doi:10.1136/bcr-2013-201065. PMC 4069815. PMID 24920510.
- ↑ Baiju CS, Rohatgi S (July 2011). “Peripheral odontogenic fibroma: A case report and review”. J Indian Soc Periodontol. 15 (3): 273–5. doi:10.4103/0972-124X.85674. PMC 3200026. PMID 22028517.
- ↑ Khot K, Deshmane S, Bagri-Manjrekar K, Khot P (2017). “Peripheral Odontogenic Fibroma: A Rare Tumor mimicking a Gingival Reactive Lesion”. Int J Clin Pediatr Dent. 10 (1): 103–106. doi:10.5005/jp-journals-10005-1416. PMC 5360813. PMID 28377665.
Risk Factors
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Maneesha Nandimandalam, M.B.B.S.[2], Simrat Sarai, M.D. [3]
Overview
There are no established risk factors for fibroma. Moreover the risk factors varies with the individual types of fibromas.
Risk Factors
Uterine fibroma
References
- ↑ Pavone D, Clemenza S, Sorbi F, Fambrini M, Petraglia F (January 2018). “Epidemiology and Risk Factors of Uterine Fibroids”. Best Pract Res Clin Obstet Gynaecol. 46: 3–11. doi:10.1016/j.bpobgyn.2017.09.004. PMID 29054502.
- ↑ Wise LA, Palmer JR, Harlow BL, Spiegelman D, Stewart EA, Adams-Campbell LL, Rosenberg L (August 2004). “Risk of uterine leiomyomata in relation to tobacco, alcohol and caffeine consumption in the Black Women’s Health Study”. Hum. Reprod. 19 (8): 1746–54. doi:10.1093/humrep/deh309. PMC 1876785. PMID 15218005.
- ↑ Dragomir AD, Schroeder JC, Connolly A, Kupper LL, Hill MC, Olshan AF, Baird DD (November 2010). “Potential risk factors associated with subtypes of uterine leiomyomata”. Reprod Sci. 17 (11): 1029–35. doi:10.1177/1933719110376979. PMID 20693498.
- ↑ Gao M, Wang H (October 2018). “Frequent milk and soybean consumption are high risks for uterine leiomyoma: A prospective cohort study”. Medicine (Baltimore). 97 (41): e12009. doi:10.1097/MD.0000000000012009. PMC 6203589. PMID 30313022.
Screening
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Maneesha Nandimandalam, M.B.B.S.[2], Simrat Sarai, M.D. [3]
Overview
According to the United States Preventive Services Task Force, screening for fibroma is not recommended among the general population.
Risk Factors
According to the United States Preventive Services Task Force, screening for fibroma is not recommended among the general population.[1]
References
- ↑ http://www.uspreventiveservicestaskforce.org/BrowseRec/Search?s=fibroma Accessed on March 10, 2016.
Differentiating Fibroma from other Diseases

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Maneesha Nandimandalam, M.B.B.S.[2], Simrat Sarai, M.D. [3]
Overview
Oral fibroma must be differentiated from squamous papilloma, giant cell fibroma, neurofibroma, peripheral giant cell granuloma, mucocele, and benign and malignant salivary gland tumors. Non-ossifying fibroma must be differentiated from fibrous cortical defect, aneurysmal bone cyst, chondromyxoid fibroma, fibrous dysplasia, desmoplastic fibroma, giant cell tumor of bone, and spindle cell lesions of bone. Ossifying fibroma must be differentiated from ossifying fibroma, fibrous dysplasia, adamantinoma, and osteoid osteoma. Chondromyxoid fibroma must be differentiated from aneurysmal bone cyst (ABC), giant cell tumor of bone (GCT), non-ossifying fibroma, chondroblastoma, chondrosarcoma, and phosphaturic mesenchymal tumor. Desmoplastic fibroma must be differentiated from giant cell tumor of bone (GCT), non- ossifying fibroma (NOF), fibrous dysplasia, low grade fibrosarcoma, unicameral bone cyst, chondromyxoid fibroma, periosteal desmoids, eosinophilic granuloma, low-grade intraosseous osteosarcoma, adamantinoma, and distant metastasis.
Differential Diagnosis
| Type of Fibroma | Differential Diagnosis |
|---|---|
|
|
| |
|
|
| |
| |
|
Considerations for extremely well defined lesions include:
If not extremely well defined, broader considerations include:
Also consider the differential for a single pleural mass which includes the following:
| |
| |
|
|
|
|
| |
| |
|
|
| |
| |
|
References
Natural History, Complications & Prognosis
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Maneesha Nandimandalam, M.B.B.S.[2], Simrat Sarai, M.D. [3]
Overview
Common complications of chondromyxoid, ossifying and non-ossifying fibroma include pathological fractures. Depending on the type of the fibroma, the prognosis may vary. However, the prognosis is generally regarded as excellent for nonossifying fibroma. Ossifying fibromas tend to regress over time. Ossifying fibroma is noninvasive tumor. It will recur if it is excised before skeletal maturity. Excision after skeletal maturity is usually successful. Oral fibromas are benign tumors. Recurrence of oral fibromas is possible, however, if the offending irritant persists. Desmoplastic fibromas are benign and locally aggressive tumors. Desmoplastic fibroma is a rare benign intraosseous tumor neoplasm. Desmoplastic fibroma has a recurrence rate of approximately 37% to 72%. The average rate of recurrence after curettage has been reported to be approximately 55%.
Natural History
Cemento-ossifying fibroma
- Clinically, cemento-ossifying fibroma manifest as a slow-growing intrabony mass that is normally well delimited and asymptomatic, although over time the lesion may become large enough to cause facial deformation. Cemento-ossifying fibroma is a benign fibro-osseous maxillary tumor. It is a slow-growing lesion. Approximately one-half of all cases are asymptomatic, the growth of the tumor over time may lead to facial asymmetry, with the appearance of a mass causing facial discomfort or mandibular expansion, and the possible displacement of dental roots. Juvenile aggressive cemento-ossifying fibroma presents in children and is clinically more aggressive and pathologically more vascular.[1]
- Central cemeto-ossifying fibromas are a distinct form of benign fibro-osseous lesions of the maxilla and mandible. Central cemento-ossifying fibromas are asymptomatic if they are not expanded. Therefore, they are generally not diagnosed until the tumor has had time to produce calcifications. Central cemento-ossifying fibromas are typically well-circumscribed, they maintain a round shape, expand the surrounding cortical bone without cortical expansion, and may cause tooth divergence. The expanded tumors may involve the nasal septum, orbital floor, and infraorbital foramen. At the time of diagnosis, maxillary central cemento-ossifying fibromas are large; indicating the ability of the tumor to expand freely within the maxillary sinus.[2][3][4][5][6]
Chondromyxoid Fibroma
- Chondromyxoid fibroma (CMF) is a rare, slow-growing, benign bone tumor of chondroblastic derivation. Approximately 70% of patients with chondromyxoid fibroma have symptoms at the time of diagnosis; the remaining lesions are found incidentally. Chondromyxoid fibroma (CMF) represents less than 1% of all benign bone neoplasms. It is a slow-growing, locally destructive tumor.[7] Pain is the most common symptom and may be present for years. While typically mild, the pain may become severe with time, and night symptoms may be present. Patients may also report stiffness and swelling. As a consequence of slow growth of the tumor, pathologic fractures have been rarely reported. Chondromyxoid fibroma is an unusual benign tumor of cartilaginous tissues.[8][9][10][11][12]
Oral Fibroma
- A history of chronic irritation to the area or trauma followed by the development of a sessile, firm mass is characteristic of oral fibroma. The majority of fibromas represent reactive focal fibrous hyperplasia due to local irritation or trauma. The fibroma may occur in any area, although the areas most frequently affected include the areas most easily traumatized, such as the tongue, buccal mucosa, and labial mucosa. They are benign lesions and they do not have malignant potential and recurrence is mostly as a result of failure to eliminate the irritation. Oral fibroma generally presents as a painless, sessile, ovoid or round, broad based growth. Oral fibromas develop over weeks or months to reach a maximum size which is approximately 1 cm in diameter, but can sometimes be larger.[13][14][15][16]
Desmoplastic Fibroma
- Desmoplastic fibroma (DF) is an extremely rare benign intraosseous tumor with locally aggressive and infiltrative characteristics. The clinical presentation of desmoplastic fibroma is nonspecific and usually presents as pain over the affected area and occasionally as a palpable mass, although pathologic fracture has been described previously as a common reason for seeking treatment. Desmoplastic fibroma has also been presented as an incidental finding. The most common sites of involvement are the mandible and the metaphysis of long bones. Biologically and histologically, desmoplastic fibroma mimics extra-abdominal desmoid tumor of soft tissue. Morphologically a distinction between desmoplastic fibroma and aggressive fibromatosis (desmoid tumor) is not possible.[17][18][19]
Non-ossifying Fibroma
- Nonossifying fibroma (NOF) is a common type of benign fibrous lesion that occurs in the metaphysis of the long bones of the lower extremities. While the NOF occurs with relative frequency in the long bones, NOF of the mandible and other areas of the skeleton are rare. The majority of NOFs are asymptomatic; however, those that are particularly large may cause chronic pain and/or pathologic fracture in the long bones. Diagnosis of NOF in the long bones is usually based upon the characteristic clinical and radiographic appearance. Typically the NOF appears as an asymptomatic multiloculated lesion often identified incidentally during radiographic evaluation indicated for another reason. Mandibular lesions of the NOF may be asymptomatic or may present with expansion. Non-ossifying fibromas are typically self-limiting and spontaneous resolution at skeletal maturity is usually seen. This spontaneous regression, usually starting at the end of adolescence, has been observed to occur over periods of 29–52 months. Recurrence is rare. The clinical behavior of mandibular NOF appears to be that of a benign lesion with no reports of recurrence, as seen in the long bones.[20][21][22][23]
Complications
Ovarian Fibroma
Ossifying- Fibroma
- Pathological fracture(s)
- Limb bowing
Non-ossifying Fibroma
Chondromyxoid fibromas
Uterine Fibromas
- Rarely invasion of adjacent venous channels leading to intravenous leiomyomatosis [27][28][29][30][31]
- Rarely (0.1-0.5%), they undergo malignant degeneration into leiomyosarcomas
- In extremely rare instances, lesions capable of metastasizing without malignant transformation: benign metastasizing leiomyoma
- Fibroids may undergo torsion, leading to acute pelvic pain
- Hemoperitoneum
- Hypovolemic shock from massive haemorrhage
Prognosis
Non-ossifying Fibroma
- Generally, the prognosis for nonossifying fibroma is excellent. They usually fill in during adolescence. The risk of recurrence is usually lower than for other benign tumors.[32]
Oral Fibromas
- Oral fibromas are benign tumors. Recurrence of oral fibromas is possible, however, if the offending irritant persists.
Ovarian Fibromas
- Ovarian fibromas are almost always benign.
Ossifying Fibroma
- Ossifying fibromas tend to regress over time. For locally aggressive lesions, surgical resection is often curative although recurrence has been reported. Ossifying fibroma is noninvasive tumor. It will recur if it is excised before skeletal maturity. Excision after skeletal maturity is usually successful.[33][34]
Pleural Fibroma
- The majority of pleural fibromas tend to be benign and slow growing. Approximately 78% to 88% of SFT’s(solitary fibrous tumors) are benign and 12% to 22% are malignant. In approximately 10 to 25 percent of cases recurrence of the tumor can occur. Late relapse, even for benign tumors, is common.
- Approximately 63% of patients with malignant pleural fibromas will have a recurrence of their tumor, of which more than half will succumb to disease progression within 2 years.
- Among tumors classified as malignant, approximately 10 to 40 percent of those destined to metastasize will do so after five years, and they may recur up to 20 years after initial presentation . Prolonged survival after pleural fibroma recurrence is possible, particularly for those who are amenable to re-resection. Patients with multiple synchronous metastases that are not amenable to surgical intervention, usually have a poor prognosis.
- Recurrence in pleural fibromas may be due to following causes:
- Incomplete resection
- Tumor seeding within the pleura, peritoneum or meninges, or distant hematogenous spread.
- The most common sites of distant metastasis in SFT at all sites are lung, liver, bone, and brain
Chondromyxoid-Fibroma
- Chondromyxoid-fibroma are benign lesions and malignant degeneration is rare. Chondromyxoid-fibromas have a high recurrence rate of approximately 25%.
Cemento-ossifying Fibroma
- Recurrence following complete excision of cemento-ossifying fibroma is generally considered to be uncommon. However, in some series, it has been reported to be approximately 16%.
Desmoplastic Fibroma
- Desmoplastic fibromas are benign and locally aggressive tumors. Desmoplastic fibroma is a rare benign intraosseous tumor neoplasm. It is usually a localized lesion with propensity for cortical bone perforation and recurrence. They are considered to be a bony counterpart of soft tissue desmoid tumors and are histologically identical. [35] Desmoplastic fibroma has a recurrence rate of approximately 37% to 72%. The average rate of recurrence after curettage has been reported to be approximately 55%.[17]
Sclerotic Fibroma
- Sclerotic fibroma is an uncommon benign fibrous neoplasm and may be solitary or multifocal.
Uterine Fibroma
- About 1 out of 1000 lesions are or become malignant, typically as a leiomyosarcoma on histology. A sign that a lesion may be malignant is growth after menopause. There are a number of rare conditions in which fibroids metastasize. They still grow in a benign fashion, but can be dangerous depending on their location.
Peripheral odontogenic fibroma
- Recurrence is rare
Giant cell fibroma
- Giant cell fibroma is a benign non-neoplastic lesion. Recurrence is rare.
References
- ↑ Silvestre-Rangil, J.; Silvestre, FJ.; Requeni-Bernal, J. (2011). “Cemento-ossifying fibroma of the mandible: Presentation of a case and review of the literature”. Journal of Clinical and Experimental Dentistry: e66–e69. doi:10.4317/jced.3.e66. ISSN 1989-5488.
- ↑ Hekmatnia A, Ghazavi A, Saboori M, Mahzouni P, Tayari N, Hekmatnia F (2011). “A case report of cemento-ossifying fibroma presenting as a mass of the ethmoid sinus”. J Res Med Sci. 16 (2): 224–8. PMC 3214308. PMID 22091236.
- ↑ Naik RM, Guruprasad Y, Sujatha D, Gurudath S, Pai A, Suresh K (January 2014). “Giant cemento-ossifying fibroma of the mandible”. J Nat Sci Biol Med. 5 (1): 190–4. doi:10.4103/0976-9668.127326. PMC 3961933. PMID 24678226.
- ↑ Jayachandran S, Meenakshi R (2004). “Cemento ossifying fibroma”. Indian J Dent Res. 15 (1): 35–9. PMID 15682795.
- ↑ El-Mofty SK (November 1999). “Cemento-ossifying fibroma and benign cementoblastoma”. Semin Diagn Pathol. 16 (4): 302–7. PMID 10587273.
- ↑ Dewan HS, Dewan SK, Bahl S, Tushar Parekh P (October 2016). “Cemento-ossifying fibroma of mandible mimicking complex composite odontome”. BMJ Case Rep. 2016. doi:10.1136/bcr-2016-216053. PMC 5073669. PMID 27797795.
- ↑ Khalatbari, Mahmoud; Hamidi, Mehrdokht; Moharamzad, Yashar (2012). “Chondromyxoid Fibroma of the Anterior Skull Base Invading the Orbit in a Pediatric Patient: Case Report and Review of the Literature”. Neuropediatrics. 43 (03): 140–145. doi:10.1055/s-0032-1307460. ISSN 0174-304X.
- ↑ E., Estrada-Villaseñor; E., Delgado Cedillo; G., Rico Martínez; R., Delgado Chávez (2005). “Periosteal chondromyxoid fibroma: A case study using imprint cytology”. Diagnostic Cytopathology. 33 (6): 402–406. doi:10.1002/dc.20357. ISSN 8755-1039.
- ↑ McGrory BJ, Inwards CY, McLeod RA, Sim FH (1995). “Chondromyxoid fibroma”. Orthopedics. 18 (3): 307–10. PMID 7761324.
- ↑ White PG, Saunders L, Orr W, Friedman L (1996). “Chondromyxoid fibroma”. Skeletal Radiol. 25 (1): 79–81. PMID 8717127.
- ↑ Schutt PG, Frost HM (1971). “Chondromyxoid fibroma”. Clin Orthop Relat Res. 78: 323–9. PMID 5110934.
- ↑ RALPH LL (1962). “Chondromyxoid fibroma of bone”. J Bone Joint Surg Br. 44-B: 7–24. PMID 14038586.
- ↑ Regezi, Joseph A., James J. Sciubba, and Richard C. Jordan. Oral Pathology Clinical Pathologic Correlations. City: Elsevier Health Sciences, 2015. Print.
- ↑ Rangeeth, B. N., Joyson Moses, and Veera Kishore Kumar Reddy. “A rare presentation of mucocele and irritation fibroma of the lower lip.” Contemporary clinical dentistry 1.2 (2010): 111.
- ↑ Vilmann, A., P. Vilmann, and H. Vilmann. “Pyogenic granuloma: evaluation of oral conditions.” British journal of oral and Maxillofacial surgery 24.5 (1986): 376-382.
- ↑ Kolte, Abhay P., Rajshri A. Kolte, and Tushar S. Shrirao. “Focal fibrous overgrowths: A case series and review of literature.” Contemporary clinical dentistry 1.4 (2010): 271.
- ↑ 17.0 17.1 Nedopil A, Raab P, Rudert M (2013). “Desmoplastic fibroma: a case report with three years of clinical and radiographic observation and review of the literature”. Open Orthop J. 8: 40–6. doi:10.2174/1874325001307010040. PMC 3583030. PMID 23459513.
- ↑ Schneider M, Zimmermann AC, Depprich RA, Kübler NR, Engers R, Naujoks CD, Handschel J (November 2009). “Desmoplastic fibroma of the mandible–review of the literature and presentation of a rare case”. Head Face Med. 5: 25. doi:10.1186/1746-160X-5-25. PMC 2787487. PMID 19930688.
- ↑ Apaydin M, Gelal F, Avci A, Adinas C, Sarsilmaz A, Varer M (October 2008). “Desmoplastic fibroma in humerus”. J Med Imaging Radiat Oncol. 52 (5): 489–90. doi:10.1111/j.1440-1673.2008.01989.x. PMID 19032395.
- ↑ Bowers LM, Cohen DM, Bhattacharyya I, Pettigrew JC, Stavropoulos MF (2013). “The non-ossifying fibroma: a case report and review of the literature”. Head Neck Pathol. 7 (2): 203–10. doi:10.1007/s12105-012-0399-7. PMC 3642261. PMID 23008139.
- ↑ Sakamoto, Akio; Ishii, Takeaki; Oda, Yoshinao; Iwamoto, Yukihide (2012). “Nonossifying fibroma presenting as an aneurysmal bone cyst: a case report”. Journal of Medical Case Reports. 6 (1): 407. doi:10.1186/1752-1947-6-407. ISSN 1752-1947.
- ↑ Bowers, Leah M.; Cohen, Donald M.; Bhattacharyya, Indraneel; Pettigrew, James C.; Stavropoulos, Mary F. (2012). “The Non-ossifying Fibroma: A Case Report and Review of the Literature”. Head and Neck Pathology. 7 (2): 203–210. doi:10.1007/s12105-012-0399-7. ISSN 1936-055X.
- ↑ Herget GW, Mauer D, Krauß T, El Tayeh A, Uhl M, Südkamp NP, Hauschild O (April 2016). “Non-ossifying fibroma: natural history with an emphasis on a stage-related growth, fracture risk and the need for follow-up”. BMC Musculoskelet Disord. 17: 147. doi:10.1186/s12891-016-1004-0. PMC 4820930. PMID 27044378.
- ↑ Macciò A, Madeddu C, Kotsonis P, Pietrangeli M, Paoletti AM (June 2014). “Large twisted ovarian fibroma associated with Meigs’ syndrome, abdominal pain and severe anemia treated by laparoscopic surgery”. BMC Surg. 14: 38. doi:10.1186/1471-2482-14-38. PMC 4074309. PMID 24962423.
- ↑ Okuda K, Noguchi S, Narumoto O, Ikemura M, Yamauchi Y, Tanaka G, Takai D, Fukayama M, Nagase T (May 2016). “A case of Meigs’ syndrome with preceding pericardial effusion in advance of pleural effusion”. BMC Pulm Med. 16 (1): 71. doi:10.1186/s12890-016-0241-1. PMC 4862177. PMID 27160723.
- ↑ Kortekaas KE, Pelikan HM (January 2018). “Hydrothorax, ascites and an abdominal mass: not always signs of a malignancy – Three cases of Meigs’ syndrome”. J Radiol Case Rep. 12 (1): 17–26. doi:10.3941/jrcr.v12i1.3209. PMID 29875983.
- ↑ “Bleeding associated with uterine leiomyomas. Tailor treatment to the individual patient”. Prescrire Int. 23 (149): 130–5. May 2014. PMID 24926520.
- ↑ Althobaiti FA, Alsaadi KK, Althobaiti AA (February 2019). “A Case of Hemoperitoneum Due to Spontaneous Bleeding from a Uterine Leiomyoma”. Am J Case Rep. 20: 167–170. doi:10.12659/AJCR.914573. PMC 6375281. PMID 30733430.
- ↑ Mizrahi DJ, Kaushik C, Adamo R (March 2017). “Hypovolemic Shock and Hemoperitoneum from Spontaneous Avulsion of a Large Pedunculated Uterine Leiomyoma”. J Radiol Case Rep. 11 (3): 15–21. doi:10.3941/jrcr.v11i3.3054. PMC 5441463. PMID 28584568.
- ↑ Pachy F, Lemercier D, Dommergues M, Sibony O (May 2009). “[Unusual complication of uterine leiomyoma: spontaneous avulsion with massive hemoperitoneum]”. J Gynecol Obstet Biol Reprod (Paris) (in French). 38 (3): 239–41. doi:10.1016/j.jgyn.2008.08.008. PMID 19179018.
- ↑ Hicks G, McCallum IJ, Ogah K, Guirguis M, Kasaraneni R (February 2010). “Spontaneous uterine perforation secondary to uterine leiomyosarcoma presenting as acute abdomen with haemoperitoneum”. J Obstet Gynaecol. 30 (2): 211–2. doi:10.3109/01443610903477523. PMID 20143996.
- ↑ Biermann JS (2002). “Common benign lesions of bone in children and adolescents”. J Pediatr Orthop. 22 (2): 268–73. PMID 11856945.
- ↑ McCaffrey M, Letts M, Carpenter B, Kabir A, Davidson D, Seip J (2003). “Osteofibrous dysplasia: a review of the literature and presentation of an additional 3 cases”. Am J Orthop (Belle Mead NJ). 32 (10): 479–86. PMID 14620087.
- ↑ Wang JW, Shih CH, Chen WJ (1992). “Osteofibrous dysplasia (ossifying fibroma of long bones). A report of four cases and review of the literature”. Clin Orthop Relat Res (278): 235–43. PMID 1563159.
- ↑ Cheng, A.; Ji, S.; Pogrel, M.A. (2012). “Poster 55: A Natural History of Desmoplastic Fibroma: Over 20 Years of Experience”. Journal of Oral and Maxillofacial Surgery. 70 (9): e74. doi:10.1016/j.joms.2012.06.111. ISSN 0278-2391.
Diagnosis
Diagnosis
History and Symptoms | Physical Examination | X Ray | CT | MRI | Ultrasound | Other Imaging Findings | Other Diagnostic Studies
Treatment
Treatment
Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies
See also
See also
- Peripheral ossifying fibroma
- Acrochordon (skin tags)
da:Fibrom de:Fibrom it:Fibromioma uterino
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH



















